



IN THE DISTRICT COURT OF CLEVELAND COUNTY  
STATE OF OKLAHOMA

Document split into multiple parts

STATE OF OKLAHOMA, ex rel., )  
MIKE HUNTER, )  
ATTORNEY GENERAL OF OKLAHOMA, )

**PART H**

Plaintiff, )

vs. )

Case No. CJ-2017-816  
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.; )
- (2) PURDUE PHARMA, INC.; )
- (3) THE PURDUE FREDERICK COMPANY; )
- (4) TEVA PHARMACEUTICALS USA, INC.; )
- (5) CEPHALON, INC.; )
- (6) JOHNSON & JOHNSON; )
- (7) JANSSEN PHARMACEUTICALS, INC; )
- (8) ORTHO-MCNEIL-JANSSEN )  
PHARMACEUTICALS, INC., n/k/a )
- JANSSEN PHARMACEUTICALS; )
- (9) JANSSEN PHARMACEUTICA, INC., )  
n/k/a JANSSEN PHARMACEUTICALS, INC.; )
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, )  
f/k/a ACTAVIS, INC., f/k/a WATSON )  
PHARMACEUTICALS, INC.; )
- (11) WATSON LABORATORIES, INC.; )
- (12) ACTAVIS LLC; and )
- (13) ACTAVIS PHARMA, INC., )  
f/k/a WATSON PHARMA, INC., )

Defendants. )

STATE OF OKLAHOMA } S.S.  
CLEVELAND COUNTY }

**FILED**

MAY 23 2019

In the office of the  
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2767		Duragesic Label (1-2000, 2-2001)	JAN-MS-00304304	JAN-MS-00304309		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2768		Duragesic Label 2003-05 Modified Indication Label	JAN-OK-00143079	JAN-OK-00143105		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2769		Duragesic Label 2005-02	JAN-OK-00143908	JAN-OK-00143951		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2770		Duragesic Label 2008-02	JAN-OK-00143956	JAN-OK-00144003		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2771		Duragesic Label 2009-07	JAN-OK-00143111	JAN-OK-00143156		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2772		Duragesic Label 2012-07	JAN-OK-00143212	JAN-OK-00143254		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2773		Duragesic Label 2013-09	JAN-MS-00583030	JAN-MS-00583073		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2774		Duragesic Label 2014-04	JAN-MS-00238420	JAN-MS-00238465		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2775		Duragesic Label 2016-12	JAN-OK-00144008	JAN-OK-00144063		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2776		Duragesic Label 2018-01				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2777		Nucynta Label 2008-11	JAN-OK-00142748	JAN-OK-00142774		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2778		Nucynta Label 2009-03	JAN-OK-00142778	JAN-OK-00142803		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2779		Nucynta Label 2010-10	JAN-OK-00143258	JAN-OK-00143289		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2780		Nucynta Label 2013-07	JAN-OK-00142809	JAN-OK-00142836		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2781		Nucynta Label 2013-10	JAN-OK-00142840	JAN-OK-00142867		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2782		Nucynta Label 2016-12	JAN-MS-00238666	JAN-MS-00238698		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2783		Nucynta ER Label 2011-08	JAN-OK-00142911	JAN-OK-00142949		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2784		Nucynta ER Label 2012-07	JAN-OK-00142961	JAN-OK-00142995		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2785		Nucynta ER Label 2012-08	JAN-OK-00143002	JAN-OK-00143038		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2786		Nucynta ER Label 2014-04	JAN-OK-00143044	JAN-OK-00143078		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2787		Nucynta ER Label 2016-12	JAN-MS-00238604	JAN-MS-00238636		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2788		Nucynta Oral Solution Label 2012-10	JAN-MS-01248173	JAN-MS-01248215		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2789		Nucynta Oral Solution Label 2012-11	JAN-OK-00143870	JAN-OK-00143907		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2790		Nucynta Oral Solution Label 2016-12				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2791		Duragesic Status Report Post Marketing Studies (1991-1992)	JAN-MS-00213683	JAN-MS-00213683		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2792		Duragesic NDA 12-21-1987 VOL 2	JAN-MS-00213638	JAN-MS-00213638		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2793		Duragesic NDA 12-21-1987 VOL 3	JAN-MS-00213649	JAN-MS-00213649		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2794		Duragesic NDA 12-21-1987 VOL 4	JAN-MS-00213660	JAN-MS-00213660		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2795		Duragesic NDA 12-21-1987 VOL 5	JAN-MS-00213671	JAN-MS-00213671		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2796		Duragesic NDA 12-21-1987 VOL 6	JAN-MS-00213672	JAN-MS-00213672		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2797		Duragesic NDA 12-21-1987 VOL 7	JAN-MS-00213676	JAN-MS-00213676		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2798		Duragesic NDA 12-21-1987 VOL 8	JAN-MS-00213677	JAN-MS-00213677		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2799		Duragesic NDA 12-21-1987 VOL 9	JAN-MS-00213678	JAN-MS-00213678		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2800		Duragesic NDA 12-21-1987 VOL 10	JAN-MS-00213628	JAN-MS-00213628		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2801		Duragesic NDA 12-21-1987 VOL 11	JAN-MS-00213629	JAN-MS-00213629		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2802		Duragesic NDA 12-21-1987 VOL 12	JAN-MS-00213630	JAN-MS-00213630		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2803		Duragesic NDA 12-21-1987 VOL 13	JAN-MS-00213631	JAN-MS-00213631		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2804		Duragesic NDA 12-21-1987 VOL 14	JAN-MS-00213632	JAN-MS-00213632		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2805		Duragesic NDA 12-21-1987 VOL 15	JAN-MS-00213633	JAN-MS-00213633		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2806		Duragesic NDA 12-21-1987 VOL 16	JAN-MS-00213634	JAN-MS-00213634		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2807		Duragesic NDA 12-21-1987 VOL 17	JAN-MS-00213635	JAN-MS-00213635		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2808		Duragesic NDA 12-21-1987 VOL 18	JAN-MS-00213636	JAN-MS-00213636		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2809		Duragesic NDA 12-21-1987 VOL 19	JAN-MS-00213637	JAN-MS-00213637		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2810		Duragesic NDA 12-21-1987 VOL 20	JAN-MS-00213639	JAN-MS-00213639		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2811		Duragesic NDA 12-21-1987 VOL 21	JAN-MS-00213640	JAN-MS-00213640		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2812		Duragesic NDA 12-21-1987 VOL 22	JAN-MS-00213641	JAN-MS-00213641		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2813		Duragesic NDA 12-21-1987 VOL 23	JAN-MS-00213642	JAN-MS-00213642		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2814		Duragesic NDA 12-21-1987 VOL 24	JAN-MS-00213643	JAN-MS-00213643		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2815		Duragesic NDA 12-21-1987 VOL 25	JAN-MS-00213644	JAN-MS-00213644		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2816		Duragesic NDA 12-21-1987 VOL 26	JAN-MS-00213645	JAN-MS-00213645		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2817		Duragesic NDA 12-21-1987 VOL 27	JAN-MS-00213646	JAN-MS-00213646		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2818		Duragesic NDA 12-21-1987 VOL 28	JAN-MS-00213647	JAN-MS-00213647		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2819		Duragesic NDA 12-21-1987 VOL 29	JAN-MS-00213648	JAN-MS-00213648		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2820		Duragesic NDA 12-21-1987 VOL 30	JAN-MS-00213650	JAN-MS-00213650		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2821		Duragesic NDA 12-21-1987 VOL 31	JAN-MS-00213651	JAN-MS-00213651		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2822		Duragesic NDA 12-21-1987 VOL 32	JAN-MS-00213652	JAN-MS-00213652		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2823		Duragesic NDA 12-21-1987 VOL 33	JAN-MS-00213653	JAN-MS-00213653		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2824		Duragesic NDA 12-21-1987 VOL 34	JAN-MS-00213654	JAN-MS-00213654		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2825		Duragesic NDA 12-21-1987 VOL 35	JAN-MS-00213655	JAN-MS-00213655		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2826		Duragesic NDA 12-21-1987 VOL 36	JAN-MS-00213656	JAN-MS-00213656		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2827		Duragesic NDA 12-21-1987 VOL 37	JAN-MS-00213657	JAN-MS-00213657		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2828		Duragesic NDA 12-21-1987 VOL 38	JAN-MS-00213658	JAN-MS-00213658		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2829		Duragesic NDA 12-21-1987 VOL 39	JAN-MS-00213659	JAN-MS-00213659		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2830		Duragesic NDA 12-21-1987 VOL 40	JAN-MS-00213661	JAN-MS-00213661		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2831		Duragesic NDA 12-21-1987 VOL 41	JAN-MS-00213662	JAN-MS-00213662		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2832		Duragesic NDA 12-21-1987 VOL 42	JAN-MS-00213663	JAN-MS-00213663		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2833		Duragesic NDA 12-21-1987 VOL 43	JAN-MS-00213664	JAN-MS-00213664		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2834		Duragesic NDA 12-21-1987 VOL 44	JAN-MS-00213665	JAN-MS-00213665		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2835		Duragesic NDA 12-21-1987 VOL 45	JAN-MS-00213666	JAN-MS-00213666		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2836		Duragesic NDA 12-21-1987 VOL 46	JAN-MS-00213667	JAN-MS-00213667		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2837		Duragesic NDA 12-21-1987 VOL 47	JAN-MS-00213668	JAN-MS-00213668		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2838		Duragesic NDA 12-21-1987 VOL 48	JAN-MS-00213669	JAN-MS-00213669		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2839		Duragesic NDA 12-21-1987 VOL 49	JAN-MS-00213670	JAN-MS-00213670		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2840		Duragesic NDA 12-21-1987 VOL 62	JAN-MS-00213673	JAN-MS-00213673		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2841		Duragesic NDA 12-21-1987 VOL 63	JAN-MS-00213674	JAN-MS-00213674		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2842		Duragesic NDA 12-21-1987 VOL 64	JAN-MS-00213675	JAN-MS-00213675		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2843		Duragesic NDA Medical Official Reviews Vols 1-5	JAN-MS-00551711	JAN-MS-00552054		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2844		Nucynta IR NDA Reviewer's Guide	JAN-MS-00230438	JAN-MS-00230438		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2845		Nucynta ER NDA Reviewer's Guide	JAN-MS-00214419	JAN-MS-00214419		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2846		Nucynta Oral Solution Cross-Reference to Nucynta IR Clinical Overview	JAN-MS-00230207	JAN-MS-00230207		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2847		Nucynta ER (tapentadol) Extended-Release Oral Tablets PPT	JAN-MS-00244576	JAN-MS-00244717		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2848		IWG Submission to FDA Docket	JAN-MS-00677129	JAN-MS-00677143		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2849		Agenda for May 27, 2009 meeting with FDA	JAN-MS-01048370	JAN-MS-01048379		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2850		United States Food and Drug Administration Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs Public Meeting May 27-28, 2009 PPT	JAN-MS-01048380	JAN-MS-01048380		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2851		Long-Acting Opioid Analgesics REMS	JAN-MS-01048685	JAN-MS-01048693		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2852		Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee	JAN-MS-02233933	JAN-MS-022334306		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2853		Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committees July 22-23, 2010 PPT				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2854		Opioid Risk Tool				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2855		AP-44 Clinical Development Plan Draft	JAN-MS-00618586	JAN-MS-00618589		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2856		Developmental Alternatives PPT for backup during AP-23 discussion	JAN-MS-00423428	JAN-MS-00423428		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2857		R331333 NPDC Meeting PPT	JAN-MS-02536041	JAN-MS-02536056		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2858		AP-48 Chronic Pain Steering Committee Meeting	JAN-MS-03067303	JAN-MS-03067382		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2859		Nucynta OS (Tapentadol HCl) PPT	JAN-MS-02920800	JAN-MS-02920800		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2860		Email from R. Kuntz to K. Burns re NUCYNTA LCM	JAN-MS-01040851	JAN-MS-01040851		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2861		Nucynta Oral Solution PPT	JAN-MS-01040852	JAN-MS-01040852		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2862		Email from F. Demiro to P. Yap re Oral Solution Q&A from Med Comm	JAN-MS-00336388	JAN-MS-00336388		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2863		Nucynta (tapentadol) oral solution Q & A	JAN-MS-00336389	JAN-MS-00336390		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2864		Email from GMS Support Desk to T. Hillmer re Submission of tapentadol IND and NDA Transfer Letters to the FDA	JAN-MS-02119923	JAN-MS-02119924		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2865		Allen et al., "Reference Guide on the Estimation of Economic Damages," in Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2866		Duragesic Status Report of Post Marketing Studies part of NDA (1991-1992)	JAN-MS-00213684	JAN-MS-00213684		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2867		NPEC Presentation	JAN-MS-00314079	JAN-MS-00314079		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2868		Patient Pak Folder	JAN-MS-02003178	JAN-MS-02003181		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2869		Box, George E.P., "Use and Abuse of Regression," Technometrics, 8:4, 625-629, 1966.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2870		Patient Pak Letter	JAN-MS-02003176	JAN-MS-02003177		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2871		Box, George E.P., Hunter, William G., and Hunter, J. Stuart, Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building, New York: John Wiley & Sons, 1978.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2872		Patient Pak Q&A Booklet	JAN-MS-02003148	JAN-MS-02003175		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2873		Cochran, William G., Sampling Techniques, 3rd ed., New York: John Wiley & Sons, 1977.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2874		Patient Pak Box	JAN-MS-02003182	JAN-MS-02003183		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2875		Patient Pak Coupon	JAN-MS-02003184	JAN-MS-02003185		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2876		Freedman, David, Pisani, Robert and Purves, Roger, Statistics, New York: W. W. Norton & Company, 1998.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2877		Granger, C.W.J. and Newbold, P., "Spurious Regressions in Econometrics," Journal of Econometrics, 2, 111-120, 1974.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2878		ICD-9 and ICD-10 codes associated with opioid use, "DOCD00.PDF".				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2879		Kaye, David H. and Freedman, David A., "Reference Guide on Statistics" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2880		Kish, Leslie. Survey Sampling, New York: John Wiley & Sons, 1965.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2881		Lohr, Sharon L. Sampling: Design and Analysis, 2nd ed., Boston: Brooks Cole, 2010.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2882		National Drug Code (NDC) descriptions from various sources; www.cdc.gov/drugoverdose/resources/data.html/CDC_Oral_Morphine_Milligram_Equivalents_sept_2018.xlsx www.accessdata.fda.gov www.rxlist.com				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2883		Original Complaint, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816, June 30, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2884		Phillips, P.C.B., "Understanding Spurious Regressions in Econometrics," Journal of Econometrics, 33, 311-340, 1986.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2885		Rubinfeld, Daniel L., "Reference Guide on Multiple Regression" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2886		Snedecor, G. W., and Cochran, W. G., Statistical Methods, 8th ed., Ames: Iowa State University Press, Ames, 1994.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2887		Stuart, Alan and Keith J. Ord. Kendall's Advanced Theory of Statistics, 5th ed. Oxford University Press, New York, 1987.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2888		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2001				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2889		Supplemented Exhibit G - James L. Gibson, Ph.D., The State's Expert Witness Disclosure, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816, February 5, 2019 and materials cited therein.					

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2890		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2002				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2891		Supplemented Exhibit S - Christopher J. Ruhm, Ph.D., The State's Expert Witness Disclosure, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CI-2017-816, February 5, 2019 and materials cited therein.					
J2892		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2003				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2893		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2004				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2894		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2895		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2006				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2896		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2007				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2897		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2898		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2009				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2899		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2010				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2900		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2011				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2901		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2902		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2903		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2904		UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2905		FDA Drug Master File List				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2906		Proposed and final aggregate production quota for scheduled II controlled substances for years 1990-2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2907		2007 FDA "Orange Book"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2908		2008 FDA "Orange Book"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2909		UN Single Convention on Narcotic Drugs, 1961				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2910		UN Convention on Psychotropic Substances, 1971				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2911		UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2912		DEA form 189 - application for individual manufacturing quota (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2913		DEA form 250 - application for procurement quota for controlled substance (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2914		DEA form 236 - controlled substances import/export declaration (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2915		DEA form 357 - application for permit to import controlled substances or domestic and/or scientific purposes (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2916		DEA form 161 - application for permit to export controlled substances pursuant to Section 1003(a), (b), (c) & (d), Title III, PL 91-513 (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2917		DEA form 161R - application for permit to export controlled substances for subsequent reexport (blank)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2918		Project Groundhog Legal Entity Overview	JAN-OK-00150103	JAN-OK-00150106		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2919		2012 Presentation - Understanding DEA Requirements in the Controlled Substance Supply Chain	JAN-MS-02283774			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2920		Video 1: Introduction Video	JAN-MS-00131172	JAN-MS-00131173		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2921		Video 2: Flashcard	JAN-MS-00131175	JAN-MS-00131179		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2922		Video 3: Bridging & Opening	JAN-MS-00131180	JAN-MS-00131181		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2923		Video 4: Closing Credits	JAN-MS-00131155	JAN-MS-00131156		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2924		Vortex II Post Diligence Questions	JAN-MS-02733172	JAN-MS-02733172		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2925		OK State Board of Pharmacy License Look-up for JOM Kentucky Distribution Center (License No. 88-W-1914)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2926		OK State Board of Pharmacy License Look-up for JOM New Jersey Distribution Center (License No. 88-W-2084)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2927		OK State Board of Pharmacy License Look-up for JOM New Jersey Distribution Center (License No. 88-W-607)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2928		OK State Board of Pharmacy License Look-up for JOM New Jersey Distribution Center (License No. 88-W-909)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2929		OBN Registration Look-up for JOM Kentucky Distribution Center (Reg. No. 61483)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2930		OBN Registration Look-up for JOM New Jersey Distribution Center (Reg. No. 61486)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2931		Nucynta Cycle 1 2010 Certification Sheet	JAN-OK-00137620	JAN-OK-00137621		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2932		About OBND				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2933		OHCA Pharmacy Forms (PHARM-1 to PHARM-119)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2934		OHCA Prior Authorization webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2935		Pharmacy Lock-In Program				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2936		Redacted medical records of Dr. Briggeman	OKAGSS_00110269-00110368			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2937		Redacted medical records of Dr. Sumner	OKAGSS_00110047-00110110			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2938		Narcotic Analgesics PA Criteria				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2939		Excel Spreadsheet re: doctor shopping and PMP	OBN-00004715			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2940		Powerpoint Sliddeck re PMP	OSDH-00149180			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2941		OBN Report	*OBN-00206616			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2942		All Citations, Complaints, Conclusions of Law, Findings of Fact, Immediate Suspensions, Notices of Hearing, Orders, Stipulations, and Summaries of Hearing of the Oklahoma Bureau of Narcotics and Dangerous Drugs Control, Oklahoma State Board of Medical Licensure, Oklahoma State Board of Veterinary Medical Examiners, Oklahoma Board of Dentistry, Oklahoma Board of Nursing, and Oklahoma State Board of Pharmacy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2943		All medical examiner records and autopsy reports produced by or from the Office of the Chief Medical Examiner in this litigation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2944		All data from the Fatal Unintentional Poisoning Surveillance System Database produced in this litigation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2945		All EGD Course of Action Summaries produced in this litigation	EGID0009 Production Volume			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2946		Oklahoma Healthcare Authority Website - Central Nervous System/Behavioral Health				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2947		D. Dowell, CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016, MMWR (Mar. 18, 2016) and Errata (Mar. 26, 2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2948		2016 National Drug Threat Assessment				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2949		2017 National Drug Threat Assessment				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2950		2017 Oklahoma Drug Threat Assessment				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2951		2018 Oklahoma Drug Threat Assessment				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2952		CDC. Provisional Drug Overdose Death Counts.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2953		Connecticut Accidental Drug Intoxication Deaths Office of the Chief Medical Examiner.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2954		David F. Musto and Pamela Korsmeyer, The Quest for Drug Control: Politics and Federal Policy in a Period of Increasing Substance Abuse, 1963-1981. New Haven: Yale University Press, 1983, 303p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2955		DW. Mexico Extradites El Chapo Drug Cartel Lieutenant to US.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2956		DW. Murder Rate Rises in Mexico as Drug Cartels Argue over Leadership and Profits.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2957		Harm Reduction Coalition. Fentanyl				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2958		ODC. Observatorio de Drogas de Colombia.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2959		SAMHSA. 2017 National Survey on Drug Use and Health (NSDUH)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2960		State's Complaint				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2961		Substance Abuse & Mental Health Service Administration, "Treatment Episode Data Set."				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2962		Thoum, Francisco E. Illegal Drugs, Economy and Society in the Andes. Baltimore: The Johns Hopkins University Press, 2003. ISBN 0-8018-7854-3 (pbk).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2963		UCSF. Heroin in Transition. Investigator: Daniel Ciccarone, MD, MPH Sponsor: NIH National Institute on Drug Abuse. March 15, 2015 – January 31, 2020. Available at: <a href="https://globalprojects.ucsf.edu/project/heroin-transition">https://globalprojects.ucsf.edu/project/heroin-transition</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2964		UNODC. Statistics and Data. Available at: <a href="https://data.unodc.org/drugs/heroin_and_cocaine_prices_in_eu_and_usa">https://data.unodc.org/drugs/heroin_and_cocaine_prices_in_eu_and_usa</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2965		UPI. Andres Manuel Obrador. Available at: <a href="https://www.upi.com/topic/Andres_Manuel_Lopez_Obrador/?tps=1">https://www.upi.com/topic/Andres_Manuel_Lopez_Obrador/?tps=1</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2966		US Customs and Border Protection. CBP Enforcement Statistics FY 2019.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2967		US Department of Justice, "Thirty-Two Kilos of Fentanyl Worth \$28.8 Million Seized and Two Dominican Nationals Arrested for Trafficking," 23 October 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2968		US State Department, Bureau for International Narcotics and Law Enforcement Affairs, "International Narcotics Control Strategy Report Vol. 1," March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2969		US-China Economic and Security Review Commission, "Fentanyl: China's Deadly Export to the United States," February 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2970		Nucynta fact sheet	JAN-MS-00235821	JAN-MS-00235821		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2971		Patient Booklet, Answers to Your Questions: Duragesic Fentanyl Transdermal System				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2972		Policy Levers That States Can Use To Improve Opioid Addiction Treatment And Address The Opioid Epidemic, Health Affairs Blog.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2973		CARESOURCE implements Quantity Limits on Opioids for Ohio Medicaid, CareSource.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2974		Kaiser Family Foundation. States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Opioids In Place. 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2975		OK Healthcare Authority Formulary available at <a href="http://www.okhca.org/providers.aspx?id=13550">http://www.okhca.org/providers.aspx?id=13550</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2976		2014 Oklahoma Statutes, Title 63. Public Health and Safety, §63-5030.1. Medicaid Drug Utilization Review Board				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2977		Oklahoma Health Care Authority Drug Utilization Review (DUR) Board website: <a href="http://www.okhca.org/about.aspx?id=486">http://www.okhca.org/about.aspx?id=486</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2978		Oklahoma Health Care Authority Website: <a href="http://okhca.org/providers.aspx?id=12090#34">http://okhca.org/providers.aspx?id=12090#34</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2979		University of Oklahoma Health Sciences Center, College of Pharmacy, Pharmacy Management Consultants Website: <a href="https://pharmacy.ouhsc.edu/pharmacies-services/pharmacy-management-consultants">https://pharmacy.ouhsc.edu/pharmacies-services/pharmacy-management-consultants</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2980		Appendices B-E	OKAG-00014643-146	OKAG-00014643-14673		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2981		Cohen, Joshua Patient Access Challenges Facing Abuse-Deterrent Formulations of Opioid Analgesics. MA State House Presentation. Feb. 5, 2018.	OUCOP-00021172	OUCOP-00021181		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2982		Joshua P. Cohen - Curriculum Vitae				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2983		Email from C. Le to N. Nesser	OHCA-00152507-15	DHCA-00152507-152517		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2984		Lin D, Jones C, Compton W, et al. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2985		Lin D, Jones C, Compton W, et al. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2986		DHCA-00000525-00337365; OKAG-00000139-00015519 (Description/Relevance: Selected DURB documents)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2987		OK Healthcare Authority Formulary pp. 19-21				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2988		Oklahoma Health Care Authority Drug Utilization Review (DUR) Board website				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2989		Oklahoma Health Care Authority PA Criteria for Narcotic Analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2990		Pham T, Skrepnek G, Bond C, Alfieri T, Cothran T, Keast S. Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016. Medical Care 2018; 56(8):727-735.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2991		Pharmacy Management Consultants, University of Oklahoma Health Sciences Center, College of Pharmacy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2992		Puja Seth et al., Quantifying the Epidemic of Prescription Opioid Overdose Deaths. American Journal of Public Health 2018; 108(4):500-502				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2993		CDC Recommendations Report 2016;65(No. RR-1):1-49				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2994		Rossiter L, Kirson ets., Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. Journal of Medical Economics 2014; 17(4):279-287				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2995		Saidman L: Brennan et al., The Role of Opioids in Pain Management. Anesthesia & Analgesia 2007; 105(6):1865-1866				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2996		2007 Nucynta IR IND-NDA Clinical Summary	JAN-MS-00230459	JAN-MS-00230459		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2997		2010 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235144	JAN-MS-00235144		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2998		2010 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235142	JAN-MS-00235142		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2999		2010 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235143	JAN-MS-00235143		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3000		2011 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235204	JAN-MS-00235204		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3001		2011 Nucynta Annual Report Clinical Summary	JAN-MS-00235206	JAN-MS-00235206		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3002		2011 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235205	JAN-MS-00235205		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3003		2011 Nucynta IR Annual Report Significant New Info	JAN-MS-00235210	JAN-MS-00235210		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3004		2012 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235266	JAN-MS-00235266		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3005		2012 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235264	JAN-MS-00235264		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3006		2012 Nucynta IR Annual Report Other Significant Info	JAN-MS-00235270	JAN-MS-00235270		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3007		Deposition of J. Rojas, Oklahoma v. Purdue Pharma LP, No. CI-2017-816 [Okla. Dist. Ct. TBD]				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3008		MacMillan, Francis P. - Preliminary Report of Actions Taken By the House of Delegates at its 2018 Interim Meeting				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3009		Passik, Steven D. - Current Risk Assessment and Management Paradigms: Snapshots in the Life of the Pain Specialist (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3010		Supplemental Expert Disclosures of C. Ruhm and G. Gibson					

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3011		A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3012		Only together can we improve the relief of pain; American Pain Society				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3013		Video: Smart Moves Smart Choices: <a href="http://www.smartmovessmartchoices.org/animated-video">http://www.smartmovessmartchoices.org/animated-video</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3014		[Video] Dr. Drew Haley, Kyle's Story: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#Haley,Kyles-story">http://www.smartmovessmartchoices.org/dr-drew-videos#Haley,Kyles-story</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3015		[Video] Dr. Drew School Nurses and Educators Take Action: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#nurses-and-educators">http://www.smartmovessmartchoices.org/dr-drew-videos#nurses-and-educators</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3016		[Video] Dr. Drew Q & A with Dr. Drew: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#qa-with-dr-drew">http://www.smartmovessmartchoices.org/dr-drew-videos#qa-with-dr-drew</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3017		[Video] Dr. Drew Q & A with Haley, Kyle <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#qa-with-Haley,Kyle">http://www.smartmovessmartchoices.org/dr-drew-videos#qa-with-Haley,Kyle</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3018		Dr. Drew Smart Moves for Teens Video Link				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3019		[Video] Dr. Drew Teen Prescription Drug Abuse: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#teen-prescription-abuse">http://www.smartmovessmartchoices.org/dr-drew-videos#teen-prescription-abuse</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3020		[Video] Dr. Drew What is Addiction: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#what-is-addiction">http://www.smartmovessmartchoices.org/dr-drew-videos#what-is-addiction</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3021		[Video] Dr. Drew What is Addiction: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#what-parents-can-do">http://www.smartmovessmartchoices.org/dr-drew-videos#what-parents-can-do</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3022		[Video] Dr. Drew Why Teens Abuse: <a href="http://www.smartmovessmartchoices.org/dr-drew-videos#why-teens-abuse">http://www.smartmovessmartchoices.org/dr-drew-videos#why-teens-abuse</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3023		Smart Moves Assembly Flier: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_AssemblyFlier_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_AssemblyFlier_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3024		Educator Survey: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_EducatorSurvey_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_EducatorSurvey_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3025		Smart Moves Parent Flier: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_ParentFlier_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_ParentFlier_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3026		Student Post-Test: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Post-Test_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Post-Test_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3027		Student Pre-Test: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Pre-Test_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Pre-Test_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3028		Small Things Can Be Deadly Poster: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SmallThingsPoster_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SmallThingsPoster_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3029		Small Things Can Be Deadly Poster: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingSpeakers_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingSpeakers_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3030		[Poster] Small Things Can Be Deadly:  <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingVideos_Web.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingVideos_Web.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3031		Teen Prescription (Rx) Drug Abuse Awareness School Tool Kit: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Web_HiRes.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Web_HiRes.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3032		[Video] Discussion Guide: <a href="http://www.smartmovessmartchoices.org/pdfs/SmartMovesSmartChoices_AnimatedVideo_DiscussionGuide.pdf">http://www.smartmovessmartchoices.org/pdfs/SmartMovesSmartChoices_AnimatedVideo_DiscussionGuide.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3033		[Poster] Start Smart Basics: <a href="http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_BasicsPoster.pdf">http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_BasicsPoster.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3034		Start Smart Infographic 1: <a href="http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic1.pdf">http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic1.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3035		Start Smart Infographic 1: <a href="http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic2.pdf">http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic2.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3036		Start Smart Infographic 1: <a href="http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_KidsArePricelessPoster.pdf">http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_KidsArePricelessPoster.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3037		Start Smart Medicine Safety Tips: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_MedicineSafetyTips.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_MedicineSafetyTips.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3038		Start Smart Parent Fact Sheet: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_ParentFactSheet.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_ParentFactSheet.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3039		Start Smart Program Overview: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_ProgramOverview.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_ProgramOverview.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3040		[Poster] Start Smart Their Drug of Choice: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_TheirDrugOfChoice_Poster.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_TheirDrugOfChoice_Poster.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3041		[Poster] Start Smart Their Drug of Choice: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_Workbook_3-5.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_Workbook_3-5.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3042		Start Smart K-2 Workbook: <a href="http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_Workbook_K-2.pdf">http://www.smartmovesmartchoices.org/pdfs/Start%20Smart_Workbook_K-2.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3043		Prescription Opioids - Drug Overdose - CDC Injury Center: <a href="http://www.cdc.gov/drugoverdose/opioids/prescribed.html">www.cdc.gov/drugoverdose/opioids/prescribed.html</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3044		Drug Facts: Prescription Opioids, National Institute on Drug Abuse (NIDA): <a href="http://www.drugabuse.gov/publications/drugfacts/prescription-opioids">www.drugabuse.gov/publications/drugfacts/prescription-opioids</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3045		[scientific article] A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3046		[Website] ASPMN: "Formation & Early History of ASPMN"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3047		[Website] APF: About APF				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3048		[Website] AIPM: "Our Mission"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3049		[Website] AIPM: Policy & Advocacy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3050		RESOLVE (Randomized Enrollment Study of Opioid Long-term use to evaluate Efficacy)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3051		[Letter] Minutes of Medical Affairs Pain/ Mycology Core Team Meeting	JAN-MS-00310362			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3052		[Chart] re drugs across PCPs and PMs.	JAN-MS-00398830			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3053		Duragesic Script for speaking to doctors	JAN-MS-00778807			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3054		Duragesic Selling Visual Aid	JAN-MS-00778811			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3055		Marketing Best Practices Council	JAN-MS-00780199			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3056		Powerpoint - General Incentive Feedback	JAN-MS-00868424			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3057		5 Point Annotation for Project Consulting for NeoPathways	JAN-MS-00813165			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3058		Email from Michelle Wanat to David Moore: FW: ACTION REQUESTED: NeoPathways Slide Deck for your review	JAN-MS-01136209			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3059		How to Talk to Your Healthcare Professional				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3060		How to Talk to Your Healthcare Professional				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3061		"Pain Control That Goes On" Ad				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3062		"Chronic Pain Control that Goes On" Ad				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3063		"Stops the Pain. Not the Patient" Ad				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J3064		"Around-the-Clock Living" Ad				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3065		"Write What You Know" Ad				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3066		"Efficacy You Need, Tolerability You Want" Ad	JAN-MS-02387666			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3067		"Are Your Patients Ready for a Change" Ad	JAN-MS-02556177			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3068		Community Connect Discussion Guide	JAN-MS-03745431			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3069		Email from Ron Kuntz to David Lin re Grant Proposal	JAN-MS-02347087			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3070		Promoting Inter-professional cooperation in Pain Care: Reconciling the roles of prescribers and dispensers A Request for Grant Support	JAN-MS-02347089			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3071		[Video] LTP Episode 6: Safe Use of Medical Devices (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3072		[Video] LTP Episode 5: Safe Use of Medical Devices (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3073		[Video] LTP Episode 4: Safe Use of Over-the-County Medications (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3074		[Video] LTP Episode 3: Safe Use of Over-the-County Medications (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3075		[Video] LTP Segment 2: Safe use of opioids				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3076		LTP Episode 1: Safe Use of Opioids (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3077		[Video] LTP Introduction (PainSAFE)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3078		[Video] LTP Denise Colman: In Depth Profile				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3079		[Video] LTP Episode 4: Thinking and Feeling About Pain				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3080		[Video] LTP Episode 5 - Maintaining an Active Life with Pain: Integrative Pain Management				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3081		[Video] LTP Episode 3: Communicating about Pain: For People with Pain				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3082		[Video] LTP Episode 2: Communicating about Pain for Healthcare Practitioners				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3083		[Video] LTP Episode 1: Tackling the Challenges of Pain and Pain Management				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3084		[Video] Kathy Church: In Depth Profile				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3085		Smart Moves, Smart Choices - A Prescription Drug Abuse Prevention Program	JAN-MS-00275522			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3086		Start Smart Medication Safety Basics	JAN-MS-00428531			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3087		Public Law 106-386: Victims of Trafficking and Violence Protection Act of 2000				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3088		Prescribe Responsibly Overview	JAN-MS-00318469			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3089		Email from Deem-Eshelman to Carissa Hornbeck re FOR REVIEW: Prescribe Responsibility	JAN-MS-00318468			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3090		[Website] Confronting the Opioid Epidemic				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3091		Spreadsheet] NUCYNTA Overview of Tapentadol Abuse	JAN-MS-00418497			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3092		Nucynta Ad - David's Patient Profile	JAN-MS-00235897			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3093		About Nurse.com: Nurse.com				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3094		Responsible Opioid Prescribing CME [Nurse.com]				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3095		Prescription Drug Abuse CME [Nurse.com - Prescription Drug Abuse]				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3096		Pain Management and Ethics: What's the Right thing to do Webinar [Nurse.com]				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3097		Chronic Pain: How do we treat it in an era of increasing prescription [Nurse.com - Chronic Pain]				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3098		Nucynta ER Dosing and Titration Guide	JAN-MS-00577278			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3099		Nucynta/Nucynta ER Pharmacy Guide	JAN-MS-00577291			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3100		Nucynta ER Brochure	JAN-MS-00577303			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3101		Nucynta Brochure	JAN-MS-00577309			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3102		Nucynta Brochure	JAN-MS-00577314			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3103		Nucynta Brochure	JAN-MS-00577322			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3104		Nucynta ER Brochure	JAN-MS-00577327			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3105		"Around-the-Clock Living" Ad	JAN-MS-02376708			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3106		"Write What You Know" Ad	JAN-MS-02013574			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3107		"Write What you Know" Ad - Variation	JAN-MS-00588646			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3108		"Duragesic - A Trusted Choice" Ad	JAN-MS-03073317			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3109		[PowerPoint] Game On	JAN-MS-00466843			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3110		[PowerPoint] Duragesic Matrix: CCC/MC Training Module	JAN-MS-02002550			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3111		E-Learning Courses for Pain	JAN-MS-00273068			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3112		[Presentation] Health Care Compliance (Cycle 2 - 2010)	JAN-MS-00857332			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3113		[PowerPoint] Frequently Asked Health Care Compliance Questions (Cycle 1 - 2010)	JAN-MS-00877293			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3114		Chemical Handler's Manual, Appendix E-3, United States Department of Justice Drug Enforcement Administration				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3115		2017 CVS Quantity Limit Criteria for Suboxone.	EGID-00204218	EGID-00204220		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3116		Medical Records	OKAGSS_00036133	OKAGSS_00036163		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3117		Medical Records	OKAGSS_00077627	OKAGSS_00077674		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3118		Medical Records	OKAGSS_00110047	OKAGSS_00110078		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3119		Medical Records (OKAGSS_00110313-DKAGSS_00110339)	OKAGSS_00110313	OKAGSS_00110339		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3120		Medical Records	OKAGSS_00180747	OKAGSS_00180788		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3121		Medical Records	OKAGSS_00180975	OKAGSS_00181078		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3122		Oklahoma Senate Bill 1446				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3123		Supplemental Expert Disclosures of C. Ruhm and G. Gibson					
J3124		PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-0000330			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3125		PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-0000344			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3126		PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-0000405			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3127		[Report/Memo] Janssen Pain Management Project, Institutional Direction Memo	JAN-MS-00001024			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3128		[Transmittal] Let's Talk Pain Medication Safety Series Segment 1: Safe Use of Opioids	JAN-MS-00006663			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3129		[Transmittal] Let's Talk Pain Medication Safety Series	JAN-MS-00006687			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3130		Copy Review Submission Cover Sheet: Let's Talk Pain Medication Safety Series, Segment 2: Safe Use of Opioids	JAN-MS-00006698			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3131		Copy Review Submission Cover Sheet: Let's Talk Pain Medication Safety Series, Segment 4: Safe Use of OTC Medications	JAN-MS-00006761			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3132		Copy Review Submission Cover Sheet: Let's Talk Pain Medication Safety Series, Segment 3: Safe Use of OTC Medications	JAN-MS-00006813			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3133		[Cover Sheet] ST101 Nucynta Materials	JAN-MS-00105725			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3134		The Neo Pathways Campaign: An Annotated Guide	JAN-MS-00126905			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3135		Nucynta Presentation: Workshop 3: Questions and Concerns	JAN-MS-00129495			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3136		[Report/Memo] Training & Development Material Review Project Cover Sheet Sign-off Form for NUCYNTA Hub Mtg Materials project	JAN-MS-00131044			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3137		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213707	JAN-MS-00213707		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3138		Duragesic PSUR May, 2002-Apr 2003	JAN-MS-00213708	JAN-MS-00213708		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3139		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213709	JAN-MS-00213709		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3140		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213710	JAN-MS-00213710		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3141		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213711	JAN-MS-00213711		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3142		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213712	JAN-MS-00213712		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3143		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213713	JAN-MS-00213713		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3144		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213715	JAN-MS-00213715		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3145		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213716	JAN-MS-00213716		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3146		Duragesic PSUR May, 2002-Apr 2003	JAN-MS-00213717	JAN-MS-00213717		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3147		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213718	JAN-MS-00213718		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3148		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213719	JAN-MS-00213719		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3149		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213720	JAN-MS-00213720		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3150		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213721	JAN-MS-00213721		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3151		Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213722	JAN-MS-00213722		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3152		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213723	JAN-MS-00213723		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3153		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213724	JAN-MS-00213724		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3154		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213726	JAN-MS-00213726		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3155		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213727	JAN-MS-00213727		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3156		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213728	JAN-MS-00213728		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3157		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213729	JAN-MS-00213729		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3158		Duragesic PSUR, May 2003-Apr 2004	JAN-MS-00213730	JAN-MS-00213730		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3159		File marked as Appendix 5.1 containing Fentanyl Adverse Reaction Reports	JAN-MS-00213743			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3160		File marked as Appendix 5.2 containing Fentanyl Non-serious Adverse Reactions Report	JAN-MS-00213744			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3161		[FDA Submission] FDA Form, OMB No. 0910-0001, Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use - DURAGESIC	JAN-MS-00214154			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3162		[Nucynta ER] "Group Practices Flashcards"	JAN-MS-00229101			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3163		[Nucynta and Nucynta ER] Nucynta/Nucynta ER "Dosing and Titration Guide"	JAN-MS-00229192			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3164		[Nucynta and Nucynta ER] "Nucynta/Nucynta ER: Eligible for Reimbursement by Indiana Medicaid" Announcement	JAN-MS-00229313			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3165		[Nucynta] Nucynta "Slim Jim" Sales Aid	JAN-MS-00229335			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3166		[Nucynta ER] Nucynta ER Pamphlet	JAN-MS-00229337			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3167		[Nucynta ER] Pharmacy Stocking Kit	JAN-MS-00229607			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3168		[Nucynta ER] "NOW APPROVED: Nucynta ER - Powerful Pain Management." FDA Approval Announcement	JAN-MS-00229644			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3169		[Nucynta ER] DPN Reprint Carrier	JAN-MS-00229655			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3170		[Nucynta ER] Nucynta ER DPN Pop-Up	JAN-MS-00229775			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3171		[Nucynta and Nucynta ER] MedScape Infosite on Nucynta and Nucynta ER	JAN-MS-00229930			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3172		2253 Form for the Nucynta ER Patient Brochure	JAN-MS-00230015			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3173		Nucynta ER Patient Brochure	JAN-MS-00230017			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3174		[Powerpoint] A New Perspective For Moderate to Severe Acute Pain Relief: A Focus On the Balance of Efficacy and Tolerability	JAN-MS-00230157			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3175		[Nucynta ER] Pharmacy Stocking Kit	JAN-MS-00235806			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3176		[Nucynta ER] "NOW APPROVED: Nucynta ER - Powerful Pain Management." FDA Approval Announcement	JAN-MS-00235821			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3177		[Nucynta ER] DPN Reprint Carrier	JAN-MS-00236004			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3178		[PDF] NUCYNTA Dosing and Administrative Guide	JAN-MS-00236017			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3179		[Nucynta ER] Nucynta ER DPN Pop-Up	JAN-MS-00236198			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3180		[Nucynta and Nucynta ER] MedScape Infosite on Nucynta and Nucynta ER	JAN-MS-00236318			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3181		[Nucynta] Nationwide Reimbursement Status Email to Pharmacists	JAN-MS-00236319			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3182		[Nucynta] "Now on Formulary" Announcement	JAN-MS-00236398			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3183		Letter from FDA to Janssen re: NDA 19-13 - Duragesic (MACMIS ID #8664)	JAN-MS-00238338			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3184		Letter from J&J to Drug Marketing Advertising & Comm. re: NDA 19-813 - Duragesic (MACMIS #12386)	JAN-MS-00238401			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3185		Response to Janssen's self reported violation	JAN-MS-00238409			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3186		Response to FDA Notice of Violation	JAN-MS-00238418			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3187		Janssen Pharmaceuticals, Nucynta ER (Extended -Release Oral Tablets, Overview of Drug	JAN-MS-00244576	JAN-MS-00244717		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3188		[PowerPoint] Duragesic iOptima Analysis.	JAN-MS-00247275			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3189		[Report/Memo] DURAGESIC Brand Team, 2003 Responsibilities	JAN-MS-00247407			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3190		2009 Nucynta (tapentadol) Speaker Programs	JAN-MS-00252067			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3191		[Powerpoint] NUCYNTA - 2010 Speakers Bureau	JAN-MS-00252465			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3192		[Slide Deck] NeoPathways Appointment Flashcard	JAN-MS-00274436			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3193		[Word] Treating your moderate to severe acute pain	JAN-MS-00274525	JAN-MS-00274539		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3194		[Article] Rep "How To" Guide - Improving Pain Management in the Institution, May 2012	JAN-MS-00290395	JAN-MS-00290398		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3195		Duragesic Warning Letter Response MACMIS #12386	JAN-MS-00291332			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3196		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291384	JAN-MS-00291384		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3197		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291385	JAN-MS-00291385		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3198		Duragesic, PADER Aug 1999-Jul 2000	JAN-MS-00291386	JAN-MS-00291386		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3199		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291387	JAN-MS-00291387		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3200		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291388	JAN-MS-00291388		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3201		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291390	JAN-MS-00291390		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3202		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291391	JAN-MS-00291391		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3203		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291392	JAN-MS-00291392		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3204		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291394	JAN-MS-00291394		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3205		Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291395	JAN-MS-00291395		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3206		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291397	JAN-MS-00291397		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3207		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291398	JAN-MS-00291398		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3208		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291399	JAN-MS-00291399		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3209		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291400	JAN-MS-00291400		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3210		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291401	JAN-MS-00291401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3211		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291402	JAN-MS-00291402		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3212		Duragesic PADER, Aug 2000-Jul 2001	JAN-MS-00291403	JAN-MS-00291403		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3213		Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291405	JAN-MS-00291405		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3214		Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291406	JAN-MS-00291406		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3215		Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291407	JAN-MS-00291407		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3216		Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291408	JAN-MS-00291408		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3217		Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291409	JAN-MS-00291409		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3218		FDA Periodic Safety Update Report for Fentanyl	JAN-MS-00291427			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3219		Duragesic "Life, uninterrupted." file card for sales rep usage	JAN-MS-00299212	JAN-MS-00299218		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3220		[PowerPoint] Duragesic 2002/2003 US Public Relations Overview.	JAN-MS-00303807			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3221		[Email] Chronic Pain Management KOL bios/pictures.	JAN-MS-00303861	JAN-MS-00303861		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3222		[Word Doc] KOLs in Chronic Pain Management.	JAN-MS-00303862	JAN-MS-00303891		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3223		[Spreadsheet] 2004 Pain Team Roles and Responsibilities	JAN-MS-00305129			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3224		[Press Release] Draft press release, "National Pain Education Council (NPEC) To Educate Healthcare Professionals on Use of Opioids In Clinical Practice	JAN-MS-00305220	JAN-MS-00305221		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3225		"[Powerpoint] Slide - This day will be a lifelong memory. I'm glad chronic pain won't be a part of it."	JAN-MS-00306393	JAN-MS-00306393		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3226		[Powerpoint] Slide - Game, Uninterrupted	JAN-MS-00306394	JAN-MS-00306394		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3227		[Powerpoint] Slide - Game, Uninterrupted	JAN-MS-00306395	JAN-MS-00306395		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3228		[Powerpoint] Duragesic Life; Uninterrupted	JAN-MS-00306396	JAN-MS-00306402		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3229		[Powerpoint] Duragesic Life, Uninterrupted - Improvements in Physical & Social Functioning	JAN-MS-00306403	JAN-MS-00306409		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3230		[Powerpoint] Slide - Game, Uninterrupted	JAN-MS-00306410	JAN-MS-00306410		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3231		[Powerpoint] Slide - Game, Uninterrupted	JAN-MS-00306411	JAN-MS-00306411		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3232		[Powerpoint] Duragesic Promotion Response Modeling Project, Final Recommendations Meeting - Janssen Pharmaceutica & ZS Associates	JAN-MS-00309787			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3233		Optimizing Chronic Pain Management With Duragesic	JAN-MS-00310474			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3234		NPEC Case Study Cancer Pain	JAN-MS-00312364			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3235		NPEC Case Study Low Back Pain	JAN-MS-00312365			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3236		Duragesic Speakers Training Meeting 2002	JAN-MS-00312487			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3237		[Word Doc] Performance Update for OBP/ Janssen	JAN-MS-00313831			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3238		[Spreadsheet] Duragesic Team Status Report	JAN-MS-00314706	JAN-MS-00314712		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3239		[Powerpoint] A Different Approach to Chronic Pain Management Nucynta ER	JAN-MS-00319589			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3240		[Spreadsheet] Nucynta Status Report Updated 12.20.10	JAN-MS-00323117			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3241		[Word] TAPENTADOL Professional ISI Final (12-12--08)	JAN-MS-00327213	JAN-MS-00327214		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3242		Janssen Activities	JAN-MS-00339823	JAN-MS-00339824		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3243		Nucynta Speaker Usage_August 2011_ER & Nucynta Speaker Bureau List	JAN-MS-00340438			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3244		2012 Trained NNucynta ER Speakers 01-13-12	JAN-MS-00340750			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3245		[Powerpoint] NUCYNTA ER tapentadol extended-release tablets NEW PERSPECTIVES IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN	JAN-MS-00341647			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3246		Nucynta ER Launch Readiness Promotion Strategy 2011 presentation	JAN-MS-00344263			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3247		[Image] OPIOD EFFICACT PROVEN IN MULTIPLE PAIN MODELS (iPad)	JAN-MS-00345075	JAN-MS-00345075		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3248		[Spreadsheet] Nucynta ER Latest Thinking Tracker	JAN-MS-00346689			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3249		2014 National Advocacy Business Planning INVOKANA Advocacy Relations	JAN-MS-00353874			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3250		Health Care Compliance: Cycle 3 - 2010	JAN-MS-00356971	JAN-MS-00356971		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3251		[Spreadsheet] Beth Israel Medical Center, Department of Pain Medicine and Palliative Care, Proposed Budget to Ortho-McNeil Janssen Scientific Affairs for APT-EM training	JAN-MS-00392810			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3252		[Report/Memo] Beth Israel Medical Center Department of Pain Medicine and Palliative Care - APT-EM: Advanced Pain Treatment & Training in Emergency Medicine	JAN-MS-00392811	JAN-MS-00392813		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3253		[Report/Memo] Emerging Solutions in Pain, Educational Initiative Overview	JAN-MS-00394148	JAN-MS-00394171		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3254		[Powerpoint] Practical Strategies for the Management of Pain, Virtual Roundtable of Clinical Experts with Enduring Print & Online Publication	JAN-MS-00395013			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3255		[Letter] Renewal of PrCara Corporate membership for 2010	JAN-MS-00396166	JAN-MS-00396170		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3256		[Email] INROADS 2009 Outcomes Assessment Report (attachment)	JAN-MS-00396769			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3257		National Advocacy Directors, Health Policy and Advocacy: Mission, Vision Goal - Strategies and Tactics for Success	JAN-MS-00399877			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3258		[Email] FW: Commitment to Pain slide needed for Kati Chupa	JAN-MS-00400402			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3259		Janssen Pharmaceuticals, Inc. Fact Sheet	JAN-MS-00400407	JAN-MS-00400408		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3260		National Advocacy Directors Health Policy and Advocacy Mission, Vision, Goal Strategies and Tactics for Success in 2010	JAN-MS-00400707			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3261		[Powerpoint] Advocacy, Policy, Quality Activities - Engage advocacy partners to help define patient treatment success & access pain management options	JAN-MS-00400878			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3262		[Report/Memo] Concepts in Acute Pain Management: A Nurse's Guide to Multimodal Approaches to Drug Therapy, part of the INROADS into Pain Management series	JAN-MS-00406424	JAN-MS-00406431		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3263		[Report/Memo] Optimizing Medication: Therapy for Pain The Science and Practice of Analgesic Care, "Meet the Experts" APSMN Chapter Meeting	JAN-MS-00406432	JAN-MS-00406463		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3264		[PDF] PharmaCon Group Information	JAN-MS-00408968	JAN-MS-00408970		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3265		[PDF] Brochure for CME Symposium Challenging Cases in Chronic Pain for the Frontline Clinician	JAN-MS-00411372	JAN-MS-00411373		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3266		Brand Playbook: Key Internal Initiatives	JAN-MS-00418781			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3267		Start Smart Program Overview: Early education is the Best Medicine	JAN-MS-00428464	JAN-MS-00428466		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3268		Smart Moves, Smart Choices: Teen Prescription Drug Abuse; Animated Video Discussion Guide	JAN-MS-00428467	JAN-MS-00428473		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3269		Start Smart: Protect our Kids from Medication Accidents	JAN-MS-00428522	JAN-MS-00428522		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3270		[Presentation] Nycynta Brand Playbook - Key Internal Initiatives	JAN-MS-00430529			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3271		Prescribe Responsibly PRC Summary Letter	JAN-MS-00452372	JAN-MS-00452372		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3272		[Letter] Nycynta ER (tapenradol)	JAN-MS-00468985			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3273		[Agreement] Sponsorship Agreement between Conrad & Associates and PfiCara	JAN-MS-00474423	JAN-MS-00474429		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3274		Additional orders for Finding Relief	JAN-MS-00476731	JAN-MS-00476731		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3275		Additional orders for Pain Finding Relief program with chart of volume discount prices	JAN-MS-00476733	JAN-MS-00476734		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3276		Jaime Murphy, National Association of School Nurses April 16, 2008 Press Release	JAN-MS-00500040	JAN-MS-00500040		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3277		Tapentadol: Breaking Through Barriers to Treatment Proposal from Ketchum	JAN-MS-00500088			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3278		Smart Moves, Smart Choices A Prescription Drug Abuse Education Program: Program Success & Looking Ahead	JAN-MS-00500333			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3279		Work Order -Addendum to Master Service Agreement between PfiCara and Ruder Finn, 01/01/2007	JAN-MS-00501429	JAN-MS-00501429		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3280		[Resume] Kimberly Deem Eshleman Resume	JAN-MS-00578100	JAN-MS-00578101		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3281		[Slide Deck] Defend & Grow July 2007- December 2007	JAN-MS-00588219			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3282		[Spreadsheet] Speaker Analysis Summary 2004	JAN-MS-00588903			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3283		Duragesic Defend and Grow Goals and Actuals, July-December 2007	JAN-MS-00591674			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3284		[Powerpoint] Pain team Preliminary Targeting View; Potential Impacts to Forecast	JAN-MS-00664179			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3285		[Slide Deck] Janssen Compliance Guidelines for Promotional Speaker Bureau	JAN-MS-00670087			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3286		FOR APPROVAL: Copy Revision Recommendations - PRC Comments	JAN-MS-00753047	JAN-MS-00753059		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3287		Nucynta and Nucynta ER Label Update	JAN-MS-00755159			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3288		[Doc] Dosing and Titration	JAN-MS-00758508	JAN-MS-00758510		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3289		Nucynta ER Launch Business presentation	JAN-MS-00761749			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3290		[PowerPoint] Nucynta Patient Strategy Recommendation	JAN-MS-00772406			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3291		[Word Doc] Nucynta ER Highlights of Prescribing Information	JAN-MS-00775738	JAN-MS-00775772		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3292		[Word Doc] Pain Management Communicator Janssen Key Advisor Communication Program	JAN-MS-00777042	JAN-MS-00777042		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3293		[Powerpoint] Janssen Welcome & Introduction Pain Franchise & Market Overview	JAN-MS-00777088			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3294		[Word Doc] DEA Meeting Follow-up	JAN-MS-00777576	JAN-MS-00777577		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3295		[Presentation] Duragesic- Analgesia Franchise July 26-29, 2004	JAN-MS-00777817			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3296		[Powerpoint] Building the Business Plan for Duragesic Patent Expiry Phase 1 - Interim Update	JAN-MS-00778710			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS {Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them}
J3297		Record of FDA Contact	JAN-MS-00779361	JAN-MS-00779361		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3298		[Word Doc] KOL management and stratification prospectively defined criteria	JAN-MS-00780135	JAN-MS-00780135		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3299		[Powerpoint] 2003 Tactical Plan NPEC Objectives	JAN-MS-00780331			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3300		[Work Doc] OBP POA 1: Functionality Visual Aid	JAN-MS-00787575	JAN-MS-00787575		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3301		[Spreadsheet] 2004 Primary Care Incentive Targets	JAN-MS-00788574			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3302		[Form] American Academy of Pain management Corporate Membership Application	JAN-MS-00790017	JAN-MS-00790018		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3303		[Powerpoint] Nucynta ER Contract Training	JAN-MS-00802143			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3304		[PDF] FIELD TRAINER'S GUIDE Courses on Pain and NEO Pathways	JAN-MS-00810235	JAN-MS-00810296		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3305		Executive Summary Highlights: PMLC Advisory Board Meeting	JAN-MS-00825435			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3306		A Passion for Integrity: Speaker Compliance Guidelines	JAN-MS-00825728			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3307		[Presentation] Virtual Meeting Logistics: Overview	JAN-MS-00830520			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3308		Presentation: Nucynta Resource Guide	JAN-MS-00832890	JAN-MS-00832939		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3309		[Powerpoint] NUCYNTA ER Launch Playbook	JAN-MS-00836145			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3310		[PDF] Developing Pain Experts Tapentadol Pivotal Trials	JAN-MS-00836976			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3311		[Presentation] Medscape Pharmacologica Management of Pain Resource Center and Components Update	JAN-MS-00841491			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3312		[Presentation] Chronic Pain Advisory Board Meeting	JAN-MS-00918116			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3313		Presentation: Advocacy Partners Update in Support of Appropriate Analgesia Therapy	JAN-MS-00926857			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3314		Prescribe Responsibly Web Site Manuscript	JAN-MS-00930065	JAN-MS-00930115		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3315		[Slide Deck] Pain Management: Advocacy, Policy, Quality	JAN-MS-00933930			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3316		Advocacy, Policy, Quality Activities	JAN-MS-00940794			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3317		[Slide Deck] Abuse, Addition, and Pain Relief - Time for Change: Year in Review	JAN-MS-00943834			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3318		[Slide Deck] Outcomes Inc. Identifying Unmet Educational and Informational Needs in Pain Management	JAN-MS-00947214			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3319		[Survey] Outcomes Inc. Needs Assessment Survey	JAN-MS-00947216			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3320		Conducting a Local Community Connect Programs Sheets - Content	JAN-MS-00981697	JAN-MS-00981698		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3321		Prescribe Responsibly: A Suite of Resources to Help Improve Pain Management in Any Healthcare Setting	JAN-MS-00985076			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3322		Annotated Duragesic GOC Presentation	JAN-MS-01003931			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3323		2004 Ortho-McNeil Policy Guidelines on Advisory Boards/Consultant Meetings	JAN-MS-01008639	JAN-MS-01008639		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3324		[Slide Deck] Tapentadol Clinical Trial Recommendations	JAN-MS-01027709			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3325		Dr. Amirdelfan: Speaker Removal Letter	JAN-MS-01078133			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3326		2015 FMV & Speaker Honoraria Analysis 2015 BP	JAN-MS-01082759			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3327		New Representative 30-Day Self Study Training Calendar	JAN-MS-01117062	JAN-MS-01117075		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3328		[Word] DRAFT SUBMITTING MATERIALS FOR SALES TRAINING REVIEW	JAN-MS-01124776	JAN-MS-01124777		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3329		Draft Compliance Guidance for Sales Training Materials	JAN-MS-01124778	JAN-MS-01124782		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3330		[Spreadsheet] Tapentadol Product Launch-Training Project Management Roles & Responsibilities	JAN-MS-01124829			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3331		Prkara Pain 1H09 Call Plan Tutorial	JAN-MS-01128769			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3332		Neo Pathways Program Objectives	JAN-MS-01136251			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3333		Risk Management Tools Planned or In-Place for Marketed or To-Be Marketed Pain Products	JAN-MS-01160464			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3334		Letter from Rosebraugh to Dusek	JAN-MS-01232317	JAN-MS-01232356		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3335		Article: Tapentadol Insider - Springboard Internal Communications	JAN-MS-01234772	JAN-MS-01234773		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3336		Smart Moves, Smart Choices: A Prescription Drug Abuse Prevention Program 2008: Roll Out Plan	JAN-MS-01240300			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3337		[Word] RESULTS OF PHASE 3 STUDY SHOW TAPENTADOL IR RELIEVES ACUTE PAIN AND OFFERS FAVORABLE GASTROINTESTINAL TOLERABILITY PROFILE	JAN-MS-01241635			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3338		[Word] NEW STUDY SUGGESTS TAPENTADOL IR FOR ACUTE PAIN IS ASSOCIATED WITH IMPROVED GASTROINTESTINAL TOLERABILITY COMPARED TO OXYCODONE IR	JAN-MS-01241637			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3339		Nucynta ER Patient Brochure -- PRC markup	JAN-MS-01387187	JAN-MS-01387197		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3340		CME Task Force Meeting August 6, 2003	JAN-MS-01969372			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3341		[Email] Update on Nucynta Transition Bonus Plan	JAN-MS-01969584			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3342		[Presentation] Nucynta IR and ER 2015 Transition Bonus Program	JAN-MS-01969690			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3343		[Presentation] Nucynta Brand Overview	JAN-MS-01975159			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3344		[Presentation] Executive Summary Highlights Understanding Schedule III Analgesic Usage Advisory Board Meeting	JAN-MS-01975567			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3345		Duragesic Concomitant Strength Use Analysis	JAN-MS-01976589			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3346		[Duragesic] "Preliminary Strategies: Preliminary Working Draft, June 20, 2006": draft of Duragesic business strategies slide deck	JAN-MS-01997062			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3347		[Word] Risks and Gain, Benefits of Opioid Analgesics	JAN-MS-02206692	JAN-MS-02206692		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3348		[Word] Savings card success story	JAN-MS-02248338			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3349		Nucynta: An Advance in Multimodal Analgesic Therapy	JAN-MS-02254932			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3350		Janssen Extramural Research Program	JAN-MS-02326351			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3351		[Invitation Template] Partnership Renewal for 2014 Speakers Bureau	JAN-MS-02342126	JAN-MS-02342128		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3352		My Remarks Today	JAN-MS-02360240			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3353		List of Names for Considerations as Faculty and Leaders of the NCME	JAN-MS-02395043	JAN-MS-02395045		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3354		[Powerpoint] HOME BASE MESSAGE: Tapentadol ER is an effective prescription pain medicine that is believed to block signals in the pain pathways to relieve the amount and intensity of the pain that patients feel	JAN-MS-02402001	JAN-MS-02402001		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3355		[PDF] PADT Guidebook	JAN-MS-02493626	JAN-MS-02493627		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3356		[Word] NEW DATA SUGGEST TAPENTADOL IMMEDIATE RELEASE EFFECTIVE IN RELIEVING ACUTE PAIN FROM COMMON FOOT SURGERY	JAN-MS-02498896			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3357		Three-Party CE Educational Grant Agreement (Re Grant ID #5505)	JAN-MS-02498981			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3358		PAIN Rep Master Table May 2014	JAN-MS-02527268			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3359		[Spreadsheet] Scheduled or Completed Programs	JAN-MS-02529910			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3360		[PowerPoint] Duragesic KOL Mapping Analysis	JAN-MS-02533811			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3361		[Spreadsheet] Approved Specialties	JAN-MS-02734360			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3362		[Spreadsheet] 2014 Program Budget and Assessment	JAN-MS-02734788			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3363		[Powerpoint] NUCYNTA ER Media Briefing Key Messages Post-FDA Action	JAN-MS-02823191			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3364		[Word] NUCYNTA ER (tapentadol extended-release tablets) FDA Action Response Document for APPROVAL	JAN-MS-02823192	JAN-MS-02823199		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3365		Pharmacor: Pain Management Study - Chronic Pain Nov. 2011	JAN-MS-02948933	JAN-MS-02949151		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3366		Nucynta and Nucynta ER Dual Dosing Guides	JAN-MS-02958779	JAN-MS-02958836		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3367		[PowerPoint] Nucynta RBD Meeting	JAN-MS-02959725			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3368		JOM 2017 Suspicious Order Monitoring	JAN-MS-02964344	JAN-MS-02964345		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3369		General Policy and Procedure for the Review and Approval of Advertising, Promotional and Field Sales Force Training Materials	JAN-MS-02994505			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3370		PriCara Frequently Asked Questions, 1st Half 2006 Call Plan	JAN-MS-03041302			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3371		[Word Doc] Duragesic Patient Coupon Program Guide	JAN-MS-03072699			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3372		[Agenda] Chronic Pain: DURAGESIC Speaker Training Meeting	JAN-MS-03074478			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3373		[Word Doc] DURAGESIC Speakers Bureau 2004 Speaker Training Details & Justification [Draft]	JAN-MS-03074511			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3374		Duragesic Product Suite - Course 1: Understanding Pain	JAN-MS-03075212			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3375		Duragesic Product Suite - Course 7: Selling Duragesic	JAN-MS-03075299			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3376		Duragesic Product Suite - Course 6: Competition	JAN-MS-03075301			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3377		Duragesic Product Suite - Course 5: About Duragesic	JAN-MS-03075308			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3378		Duragesic Product Suite - Course 4: Disease States	JAN-MS-03075309			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3379		Duragesic Product Suite - Course 3: Treatment Options	JAN-MS-03075417			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3380		Duragesic Product Suite - Course 2: Pain Assessment	JAN-MS-03075534			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3381		Duragesic Speaker Bureau: December 2004 Speaker Training Details & Justification	JAN-MS-03076038			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3382		Alza Corporation's Stability Study Schedule	JAN-MS-03087748	JAN-MS-03087748		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3383		Alza Corporation's Stability Study Schedule	JAN-MS-03087753	JAN-MS-03087753		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3384		Standard Operating Procedure for the Management of the Copy Review Process	JAN-MS-03087769			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3385		Janssen Suspicious Order Monitoring Program Questionnaire	JAN-MS-03116127	JAN-MS-03116127		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3386		JOM Controlled Substance Compliance Suspicious Order Monitoring	JAN-MS-03121369	JAN-MS-03121378		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3387		Attachment to email (JAN-MS-03124006), DEA form/checklist for Importer and Exporter inspections	JAN-MS-03124008	JAN-MS-03124009		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3388		[Email] National Pain Foundation, Date Availability for Conference Call meeting on Triumph 2009	JAN-MS-03613638			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3389		Copy Review Submission Cover Sheet - Nucynta ER Patient Brochure	JAN-MS-03768436			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3390		Nucynta pharmacist vis aid	JAN-MS-03769903			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3391		[Form] Copy Review Approval Form - Neopathways	JAN-MS-03778932	JAN-MS-03778932		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3392		Nucynta ipad materials	JAN-MS-03797063	JAN-MS-03797077		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3393		Nucynta ipad materials	JAN-MS-03797345	JAN-MS-03797437		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3394		2010 Smart Moves, Smart Choices fact sheet.	JAN-MS-03917731	JAN-MS-039177312		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3395		Nucynta representative resource guide	JAN-MS-04105807	JAN-MS-04105810		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3396		[Presentation] ACCME Standards for Commercial Support of Continuing Medical Education	JAN-MS-04211271			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3397		Ortho-McNeil Status Grid_03-07-11 to Client	JAN-MS-04219750			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3398		YTD Monitored Orders (Kentucky Distribution Center)	JAN-MS-05433754	JAN-MS-05433754		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3399		Guidance Document on Support for Promotional and Educational Programs and Materials	JAN-MS-05457296	JAN-MS-05457337		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3400		February Retail ST101 Agenda	JAN-OK-00060309			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3401		Welcome to Sales Training 101	JAN-OK-00061174			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3402		Sales Training 101 Preparation	JAN-OK-00062005			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3403		New Representative Training: Administrative Activities	JAN-OK-00062040			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3404		ST101 Materials List	JAN-OK-00062944			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3405		Retail Sales Training 101 Preparation	JAN-OK-00063511			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3406		Nucynta ER Train-the-Trainer	JAN-OK-00064828			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3407		ST101 Nucynta Competition Advisor Guide	JAN-OK-00067458			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3408		ST101 Nucynta Pain Advisor Guide	JAN-OK-00067486			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3409		ST101 Nucynta Package Insert Advisor Guide	JAN-OK-00067597			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3410		Resource 1: Summary of Key Points from the PI	JAN-OK-00067617			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3411		ST101 Nucynta Visual Aid Advisor's Guide	JAN-OK-00067637			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3412		ST101 Nucynta Clinical Reprints Leader's Guide	JAN-OK-00067639			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3413		ST101 Nucynta Competition Leader's Guide	JAN-OK-00067704			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3414		ST101 Nucynta Disease State Leader's Guide	JAN-OK-00067723			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3415		ST101 Nucynta Package Insert Leader's Guide	JAN-OK-00067849			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3416		ST101 Nucynta Visual Aid Leader's Guide	JAN-OK-00067897			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3417		Nucynta ER Launch Workshop Overview	JAN-OK-00069820			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3418		Tapentadol ER DM Pull-Through Guide	JAN-OK-00081177			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3419		Competitive Marketplace: Course Summary	JAN-OK-00082377			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3420		Tapentadol ER Training Plan	JAN-OK-00086675			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3421		Cycle 1 Meeting	JAN-OK-00091711			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3422		2012 Schedule of Home Study Test 01	JAN-OK-00093129			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3423		Home Study Training Calendar for NUC and NUC ER	JAN-OK-00093422			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3424		Sales Training Standards and Certification Process	JAN-OK-00093631			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3425		New Representative Training Process: Introduction	JAN-OK-00093663			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3426		Role of Representative	JAN-OK-00093681			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3427		Training and Development Material Review: Tapentadol eLearning Materials	JAN-OK-00094442			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3428		Training and Development Material Review: Pain Primer eLearning Materials	JAN-OK-00098911			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3429		Training and Development Material Review: Tapentadol eLearning (NUCYNTA IR)	JAN-OK-00099430			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3430		Training and Development Material Review: Tapentadol eLearning	JAN-OK-00102210			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3431		Training and Development Material Review: Nucynta Field Trainer Guide	JAN-OK-00102585			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3432		Training and Development Material Review: Tapentadol Launch Training	JAN-OK-00105402			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3433		Training and Development Material Review: ST 101 Nucynta Materials	JAN-OK-00105726			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3434		OMCV Nucynta Training	JAN-OK-00106329			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3435		Training and Development Material Review: ST 101 Selling Skills	JAN-OK-00107551			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3436		Training and Development Material Review: Neo Chronic Nucynta ER	JAN-OK-00107859			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3437		Training and Development Material Review: Tapentadol ER Branded eLearning	JAN-OK-00107985			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3438		Training and Development Material Review: Nucynta ER eLearning	JAN-OK-00109564			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3439		List of Nucynta trainings from various years	JAN-OK-00118410			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3440		Response to Request for Proposal (RFP) to Tapentadol eLearning	JAN-OK-00126039			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3441		Attachment A: Statement of Work for Tapentadol eLearning	JAN-OK-00126565			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3442		Best Practices/Project Traps Tapentadol Launch Training Project	JAN-OK-00126990			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3443		February Region Cycle Meeting 24 Hour Launch	JAN-OK-00127465			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3444		Statement of Work for: Tapentadol eLearning Project 3 Additional Scope	JAN-OK-00129985			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3445		Flanary 2006 calendar showing Duragesic training	JAN-OK-00137585	JAN-OK-00137587		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3446		Training Presentation 2009	JAN-OK-00137616			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3447		[Cover Email] Regarding CNS Grant ID: CE18012 New Submission	JAN-OK-00147880			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3448		INTENTIONALLY LEFT BLANK					
J3449		World Wide Narcotics Franchise entity process flow charts	JAN-OK-00148971	JAN-OK-00148979		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3450		October 21, 2015 Groundhog Supplemental Information Presentation	JAN-OK-00149559	JAN-OK-00149571		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3451		Noramco's major competitors	JAN-OK-00150111	JAN-OK-00150111		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3452		Noramco March 2015 drug reference standards list	JAN-OK-00150118	JAN-OK-00150121		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3453		Janssen market share calculation 2013-2015	JAN-OK-00150135	JAN-OK-00150135		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3454		Noramco and Actavis - Amendment to 9/7/2004 Supply Agreement	JAN-OK-00150324			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3455		Noramco and Actavis - Third Amendment to 9/7/2004 Supply Agreement	JAN-OK-00150342			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3456		Noramco and Actavis - Supply Agreement	JAN-OK-00150347			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3457		Noramco and Teva - Development and Supply Agreement	JAN-OK-00151705			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3458		Noramco and Teva - Amendment to Development and Supply Agreement	JAN-OK-00151735			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3459		Noramco and Watson - Letter Agreement to Amend Supply Agreement dated March 4, 1999	JAN-OK-00151773			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3460		Noramco and Watson - Letter Agreement to Memorialize Supply Agreement	JAN-OK-00151809			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3461		Noramco and Watson - Amendment to Supply Agreement	JAN-OK-00151811			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3462		Noramco and Watson - Active Ingredient Supply Agreement	JAN-OK-00151821			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3463		Noramco and Watson - Amendment to Supply Agreement	JAN-OK-00151833			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3464		Noramco and Watson - Countersigned Letter Agreement (Amendment to Active Ingredient Supply Agreement)	JAN-OK-00151843			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3465		Noramco and Watson - Amended and Restated Active Ingredient Supply Agreement	JAN-OK-00151844			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3466		Noramco and Watson - Amendment to Amended and Restated Active Ingredient Supply Agreement	JAN-OK-00151890			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3467		Noramco and Watson - Second Amendment to Supply Agreement	JAN-OK-00151893			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3468		Noramco and Purdue - Master Supply Agreement	JAN-OK-00152231			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3469		Noramco and Purdue - Amendment #1 to Supply Agreement	JAN-OK-00152262			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3470		Noramco and Purdue - Amendment #2 to Supply Agreement	JAN-OK-00152269			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3471		Noramco and Purdue - Amendment #3 to Supply Agreement	JAN-OK-00152272			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3472		Noramco and Purdue - Amendment #4 to Supply Agreement	JAN-OK-00152274			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3473		Noramco and Purdue - Amendment #5 to Supply Agreement	JAN-OK-00152279			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3474		Health Care Compliance training presentation	JAN-OK-141777			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3475		Nucynta Sales Training	JAN-MS-00091615	JAN-MS-00091672		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3476		Nucynta Sales Training	JAN-MS-00091704	JAN-MS-00091806		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3477		Nucynta ER Sales Training	JAN-MS-00092138	JAN-MS-00092167		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3478		Nucynta Home Study Calendar	JAN-MS-00092190	JAN-MS-00092192		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3479		Daniels Acute Pain Article	JAN-MS-00092203	JAN-MS-00092213		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3480		Daniels Post-Op Article	JAN-MS-00092214	JAN-MS-00092225		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3481		Nucynta ER FAQs	JAN-MS-00093748	JAN-MS-00093774		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3482		Training On REMS for Nucynta ER	JAN-MS-00093821	JAN-MS-00093880		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3483		ER Sales Training	JAN-MS-00105838	JAN-MS-00105868		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3484		Nucynta iR FAQ	JAN-MS-00120596	JAN-MS-00120610		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3485		Training Doc	JAN-MS-00122286	JAN-MS-00122357		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3486		Training Slide re Compliance	JAN-MS-00122577	JAN-MS-00122648		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3487		Nucynta ER REMS	JAN-MS-00123331	JAN-MS-00123390		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3488		CDC: 50 Million Americans Have Chronic Pain, Pain News Network				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3489		NY Annotated Education Law 143 §7101-a, Certification to use therapeutic drugs				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3490		West's F. S. A. § 463.012, FL ST § 463.012				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3491		CA Business and Professional Code §3041				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3492		OHCA - Prior Authorization (Pharmacy) - includes the list of medications requiring Prior Authorization (PA).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3493		Opioids Prescribing Estimates Workgroup, Observations presented to the National Center for Injury Prevention and Control's Board of Scientific Counselors, Preparatory material for meeting on December 12, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3494		Docs related to James Gibson work product (produced 3/22/2019) R CODE FOR BOOTSTRAPPING ANALYSIS.txt					
J3495		Docs related to James Gibson work product (produced 3/22/2019) CODE FOR THE CREATION OF STRATA					
J3496		Doc related to James Gibson work product (produced 3/28/2019) BOOTSTRAP.RDS					
J3497		Docs related to James Gibson work product (produced 4/2/2019) FCA70.SPS					
J3498		Docs related to James Gibson work product (produced 4/2/2019) TYPET2.SAV					
J3499		American Pain Foundation Pain Resource Guide				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3500		APF: Pain Notebook				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3501		APS Glossary of Pain Terms				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3502		APS Pain: Current Understanding of Assessment, Management, and Treatments				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3503		NEJM: Opioid Therapy for Chronic Pain: Jane C. Ballantyne, M.D. and Jianren Mao, PhD				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3504		Substance Abuse: A Comprehensive Textbook. 4th ed.: Joyce H. Lowinson, M.D., Pedro Ruiz, M.D., Robert B. Millman, M.D., et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3505		NIDA: Pain Assessment and Documentation Tool (PADT)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3506		SoonerCare Oklahoma Health Care Authority Pain Management Program				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3507		Prescribe Responsibly home page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3508		Prescribe Responsibly full website				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3509		Smart Moves, Smart Choices About page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3510		Smart Moves, Smart Choices Elementary Smart Start Tools webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3511		Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3512		Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3513		Nurse.com Confronting the Opioid Epidemic Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3514		About Nurse.com Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3515		Nurse.com Opioid Use Disorder and Pregnancy: What Does Evidence-Based Care Look Like?				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3516		Nurse.com Health Literacy and Discharge Education: I Didn't Understand				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3517		Nurse.com Patient Counseling: Preventing and Combating Opioid Misuse				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3518		Nurse.com Meeting the Challenge of Pediatric Pain Management				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3519		Nurse.com Responsible Opioid Prescribing, Chronic Pain, and Addiction				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3520		Nurse.com Prescription Drug Abuse				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3521		Noramco sales spreadsheets	NORAMCO0000001	NORAMCO0000017		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3522		TasAlk Certification of Incorporation	NORAMCO0000018	NORAMCO0000018		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3523		.sav (OUD AND DEATHS.SAV)	OKEXPERT-00000010	OKEXPERT-00000010		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3524		American Academy of Pain Medicine and American Pain Society, The Use of Opioids for the Treatment of Chronic Pain (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3525		"Pharmacological Management of Persistent Pain in Older Persons," 57 Journal of the American Geriatrics Society 1331 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3526		A. Gottschalk, "New Concepts in Acute Pain Therapy: Preemptive Analgesia," 63 American Family Physician 1979 (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3527		A. Lipman, "Opioid Pharmacotherapy: Introduction" in Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3528		A. Romero-Sandoval, "A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain," 1219 Brain Research 116 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3529		A. Rosenblum, "Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients In Methadone Maintenance and Residential Treatment Facilities," JAMA (May 14, 2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3530		A. Schwittay, "Tapentadol Prolonged Release for Severe Chronic Pain: Results of a Noninterventional Study Involving General Practitioners and Internists," 27 Journal of Pain & Palliative Care Pharmacotherapy 225 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J3531		A. Stubhaug, "Longterm treatment of chronic neuropathic pain with the NMDA (N-methyl-D-aspartate) receptor antagonist ketamine," 41 Acta Anaesthesiol Scandinavica 329 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3532		A. Trout, "Evaluation of Vertebroplasty with a Validated Outcome Measure: The Roland-Morris Disability Questionnaire," 26 Am. J. of Neuroradiology 2652 (2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3533		A. Vinik, "Abstract: Efficacy and tolerability of tapentadol extended release (ER) in patients with chronic, painful diabetic peripheral neuropathy (DPN): results of a phase 3, randomized-withdrawal, placebo-controlled study"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3534		A. Won, "Pain in the Elderly" in Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3535		Advances in Pain Research and Therapy (J. Bonica, ed. 1979)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3536		Alza Corporation, Rationale for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl) (Footnoted Version)	JAN-MS-02908137			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3537		Alza Corporation, Rationale for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3538		American Medical Association's Letter to CDC on Comments to CDC Guidelines (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3539		American Pain Foundation, Pain Notebook				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3540		American Pain Foundation, Pain Resource Guide: Getting the Help You Need (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3541		American Pain Society, Glossary, Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain <a href="http://americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cnccp.pdf">http://americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cnccp.pdf</a> (last visited Mar. 28, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3542		American Pain Society, Pain: Current Understanding of Assessment, Management, and Treatments (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3543		American Society of Addiction Medicine, Definitions Related to the Use of Opioids for the Treatment of Pain; Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3544		American Society of Anesthesiologists Task Force on Acute Pain Management, "Practice Guidelines for Acute Pain Management in the Perioperative Setting," 100 Anesthesiology 1573 (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3545		American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section, "Practice Guidelines for Chronic Pain Management," 86 Anesthesiology 995 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3546		Assessment of Abuse Potential of Drugs: Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (Jan. 2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3547		B. Bhamb, "Survey of Select Practice Behaviors by Primary Care Physicians on the Use of Opioids for Chronic Pain," Current Medical Research and Opinion, Paper 3481 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3548		B. Bingham, "The molecular basis of pain and its clinical implications in rheumatology," Nature Clinical Practice (Jan. 2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3549		B. Darnall, "International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering," Pain Medicine (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3550		B. DiJulio, The Washington Post/Kaiser Family Foundation Survey of Long-Term Prescription Painkiller Users and Their Household Members, Kaiser Family Foundation (Dec. 2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3551		B. Jung, "The Risk of Action by the Drug Enforcement Administration Against Physicians Prescribing Opioids for Pain," 7 Pain Medicine 353 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3552		B. Lange, "Efficacy and Safety of Tapentadol Prolonged Release for Chronic Osteoarthritis Pain and Low Back Pain," 27 Adv Ther 381 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3553		B. Philip, "The Economic Impact of Opioids on Postoperative Pain Management," 14 Journal of Clinical Anesthesia 354 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3554		British Pain Society, Pain Rating Scale (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3555		C. Argoff, "Pharmacologic Management of Pain," JAOA Supplement 3 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3556		C. Argoff, "Targeted Topical Peripheral Analgesics in the Management of Pain," in Advancements in Pharmacologic Treatment of Pain (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3557		C. Cleeland, Brief Pain Inventory (Short Form) (1991)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3558		C. Nielsen, "Individual Differences in Pain Sensitivity: Measurement, Causation, and Consequences," 10 Journal of Pain 231 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3559		C. Woolf, "Pain: Moving from Symptom Control Toward Mechanism-Specific Pharmacologic Management," 140 Ann Intern Med 441 (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3560		C.M. Schade, "Opioid overdoses: Not a prescribing crisis--an addiction crisis," Dalas Medical Journal (Jan. 2019).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3561		Centers for Disease Control and Prevention Letter on CDC Guidelines Clarification (April 10, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3562		Centers for Disease Control and Prevention Letter on CDC Guidelines Clarification (Feb. 28, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3563		CSAM Committee on Treatment of Opioid Dependence, Guideline for Physicians Working in California Opioid Treatment Programs (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3564		D. Budai, "Endogenous Opioid Peptides Acting at m-Opioid Receptors in the Dorsal Horn Contribute to Midbrain Modulation of Spinal Nociceptive Neurons," Physiology (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3565		D. Dowell, "No Shortcuts to Safer Opioid Prescribing," New England Journal of Medicine (2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3566		D. Eisenberg, "Trends in Alternative Medicine Use in the United States, 1990-1997," JAMA (Nov. 11, 1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3567		D. Fishbain, "Chronic Pain-Associated Depression: Antecedent or Consequence of Chronic Pain? A Review," 13 The Clinical Journal of Pain 116 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3568		D. Gourlay, "Pain and Addiction: Managing Risk Through Comprehensive Care," 27 Journal of Addictive Diseases 23 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3569		D. Gourlay, "Universal Precautions in Pain Medicine: A Rational Approach to the Treatment of Chronic Pain," 6 Pain Medicine 107 (2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3570		D. Gourlay, "Urine Drug Testing in Primary Care: Dispelling the Myths & Designing Strategies" (undated)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3571		D. Hong, "The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia," 107 Anesthesia & Analgesia 1384 (Oct. 2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3572		D. McGinnis, Exit Wounds: A Survival Guide to Pain Management for Returning veterans and Their Families (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3573		D. Spence, "Pain revisited: Evidence for Opioids," 340 BMJ c2659 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3574		D. Turk, "Chronic Pain and Depression: Role of Perceived Impact and Perceived Control in Different Age Cohorts," 61 Pain 93 (1995)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3575		D. Wong, "Pain in Children: Comparison of Assessment Scales," Pediatric Nursing (1988)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3576		D.A. Tompkins, "Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument," 105 Drug and Alcohol Dependence 154 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3577		Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Meeting Transcript (May 28, 2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3578		Deposition of C. Argoff, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Dec. 18, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3579		Deposition of D. Mazloomdoost, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 7, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3580		Deposition of E. Krebs, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 19, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3581		Deposition of G. Schick, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 1, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3582		Deposition of J. Berry, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 21, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3583		Deposition of J. Halford, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 22, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3584		Deposition of J. Muchmore, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Dec. 8, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3585		Deposition of J. Osborne, Pharm. D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 7, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3586		Deposition of L. Webster, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 18, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3587		Deposition of P. Preslar, D.O., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 2, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3588		Deposition of P. Saigh, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Jan. 8, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3589		Deposition of S. Fishman, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 27, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3590		Dowell, Deborah - "Opioid Analgesics—Risky Drugs, Not Risky Patients" (5 June 2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3591		Duragesic Marketing Material (IAN-MS-00238370-378)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3592		E. Bennaroch, "Descending monoaminergic pain modulation: Bidirectional control and clinical relevance," Neurology (July 15, 2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3593		E. Eisenberg, "Opioids for Neuropathic Pain," The Cochrane Library (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3594		E. Kalso, "Opioids in Chronic Non-Cancer Pain: Systematic Review of Efficacy and Safety," 112 Pain 372 (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3595		E. Leskowitz, "Complementary and Alternative Medicine in Pain Management" in Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3596		E. Lynch, "The Impact of Postoperative Pain on the Development of Postoperative Delirium," 86 Anesthesia & Analgesia 781 (1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3597		E. McNaughton, "Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse," 16 Pain Medicine 131 (2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3598		E. Nestler, "Molecular Basis of Long-Term Plasticity Underlying Addiction," Nature Reviews (Feb. 2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3599		e-Pharm alert Nucynta "Reimbursement Status Nationwide" (02TLM10147) (2010)	JAN-MS-00235806	JAN-MS-00235806		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3600		Extended-Release (ER) And Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) (Jun. 2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3601		F. Brennan, "Pain Management: A Fundamental Human Right," Anesthesia and Analgesia (July 2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3602		F. Cohen, "Postsurgical Pain Relief: Patients' Status and Nurses' Medication Choices," 9 Pain 265 (1980)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3603		F. Coluzzi, "Opioid Therapy for Chronic Noncancer Pain: Practice Guidelines for Initiation and Maintenance of Therapy," 71 Minerva Anestesiologica 425 (2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3604		F. Perkins, "Chronic Pain as an Outcome of Surgery: A Review of Predictive Factors," 93 Anesthesiology 1123 (2000)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3605		FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics (May 2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3606		FDA Guide to Safe Use of Pain Medicine (April 4, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3607		Food and Drug Administration Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Draft Agenda (Jul. 23, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3608		Food and Drug Administration Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Transcript (Jul. 22, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3609		G. Koob, "Drug Addiction, Dysregulation of Reward, and Allostasis," 24 <i>Neuropsychopharmacology</i> 97 (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3610		G. Vorsanger, "Abstract: Tolerability of tapentadol immediate release (IR) versus oxycodone IR in elderly patients with low back pain or osteoarthritis pain of the hip or knee," 11 <i>Journal of Pain (Supp.)</i> S42 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3611		G. Vorsanger, "Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain," 6 <i>Journal of Opioid Management</i> 169 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3612		H. Haentzchel, "Fentanyl-TTS (Durogesic) reduces pain and improves day-time activity and night-time sleep quality in patients with pain associated with rheumatoid arthritis," 60 <i>Z. Rheumatol. (Suppl. 1)</i> 81 (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3613		H. Heit, "Addiction, Physical Dependence, and Tolerance: Precise Definitions to Help Clinicians Evaluate and Treat Chronic Pain Patients," 17 <i>Journal of Pain &amp; Palliative Care Pharmacotherapy</i> 15 (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3614		H. Heit, "Pain: Substance Abuse Issues in the Treatment of Pain," in <i>Behavioral Approaches to Pain</i> (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3615		H. Heit, "Urine Testing in Pain Medicine," 27 <i>Journal of Pain and Symptom Management</i> 260 (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3616		H. Ushijima, "Exposure to gp120 of HIV-1 Induces an Increased Release of Arachidonic Acid In Rat Primary Neuronal Cell Culture Followed by NMDA Receptor-mediated Neurotoxicity," 7 <i>European Journal of Neuroscience</i> 1353 (1995)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3617		J. Audette, "Acupuncture" in <i>Principles and Practice of Pain Medicine</i> (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3618		J. Ballantyne, "Opioid Therapy for Chronic Pain," 349 <i>New England Journal of Medicine</i> 20 (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3619		J. Boscarino, "Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria," 30 <i>Journal of Addictive Diseases</i> 185 (2011)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3620		J. Boscarino, "Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system," <i>Addiction Research Report</i> (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3621		J. Dahlhamer, "Transdermal Fentanyl Versus Sustained Release Morphine for Chronic Low Back Pain," <i>Morbidity and Mortality Weekly Report</i> (Sep. 24, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3622		J. Dersh, "Chronic Pain and Psychopathology: Research Findings and Theoretical Considerations," 64 Psychosomatic Medicine 773 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3623		J. Elander, "Factors Affecting Hospital Staff Judgments About Sickle Cell Disease Pain," Journal of Behavioral Medicine (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3624		J. Elander, "Pain management and symptoms of substance dependence among patients with sickle cell disease," 57 Social Science & Medicine 1683 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3625		J. Elander, "Understanding the Causes of Problematic Pain Management in Sickle Cell Disease: Evidence That Pseudoaddiction Plays a More Important Role Than Genuine Analgesic Dependence," Journal of Pain & Symptom Management (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3626		J. Faria, "Comparative Pharmacology and Toxicology of Tramadol and Tapentadol," 22 European Journal of Pain 827 (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3627		J. Kelly, "Prevalence and Characteristics of Opioid Use in the US Adult Population" 138 Pain 507 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3628		J. Lotsch, "Current Evidence for a Genetic Modulation of the Response to Analgesics," 121 Pain 1 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3629		J. Lusher, "Analgesic Addiction and Pseudoaddiction in Painful Chronic illness," Clin/Pain (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3630		J. Menten, Longitudinal Follow-up of TTS-Fentanyl Use in Patients with Cancer-Related Pain: Results of a Compassionate-Use Study with Special Focus on Elderly Patients, 18 Current Medical Research & Opinion 488 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3631		J. Morgan, "American Opiophobia: Customary Underutilization of Opioid Analgesics," in Controversies in Alcoholism and Substance Abuse (1986)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3632		J. Nagda, "Definition and Classification of Pain" in Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3633		J.D. Haddox, "The Use of Opioids for the Treatment of Chronic Pain," 13 The Clinical Journal of Pain 6 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3634		Janssen Pharmaceutica, Progress Note, Pain Assessment and Documentation Tool (PADT) (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3635		Joint Meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Products (Jul. 22-23, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3636		K. Auret, "Underutilisation of Opioids in Elderly Patients with Chronic Pain: Approaches to Correcting the Problem," 22 Drugs Aging 641 (2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3637		K. Jordan, "A Minimal Clinically Important Difference was Derived for the Roland-Morris Disability Questionnaire for Low Back Pain," 59 Journal of Clinical Epidemiology 45 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3638		K. Kirsh, "Initial Development of a Survey Tool to Detect Issues of Chemical Coping in Chronic Pain Patients," 5 Palliative and Supportive Care 219 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3639		K. Kroenke, "The PHQ-9: Validity of a Brief Depression Severity Measure," 16 J Gen Intern Med 606 (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3640		K. Porter-Williamson, "Pseudoaddiction," 6 Journal of Palliative Medicine 937 (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3641		K. Zeitz, "The 5-HT <sub>3</sub> Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors," 22 Journal of Neuroscience 1010 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3642		L. Allan, "Transdermal Fentanyl Versus Sustained Release Morphine for Chronic Low Back Pain," Ann Rheum Dis (Suppl. 1) (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3643		L. Torres, "Fentanyl TTS in Spain: Three years of clinical experience at Pain Units," 9 Revista de la Sociedad Espanola del Dolor 217 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3644		L. Watkins, "'Listening' and 'talking' to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids," 56 Brain Research Reviews 148 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3645		L. Webster, Opioid Risk Tool, www.PreventRxAbuse.org (last visited Mar. 28, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3646		Let's Talk Pain, Resources for Pain Management, <a href="http://letstalkpain.info/">http://letstalkpain.info/</a> , accessed 8/28/2014 9:26:14 AM.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3647		Letter from M. Mulligan, Regulator Manager, Janssen Research & Development LLC to B. Rappaport, FDA re: NDA 19-813/S-043	JAN-MS-00700680	JAN-MS-00700681		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3648		M. Afllalo, "Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee A Randomized, Double Blind, Placebo- and Active-Controlled Phase III Study," 30 Clinical Drug Investigation 489 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3649		Medical records	OKAGSS_00036133	OKAGSS_00036162		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3650		Medical records	OKAGSS_00077627	OKAGSS_00077674		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3651		Medical records	OKAGSS_00110047	OKAGSS_00110078		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3652		Medical records	OKAGSS_00110313	OKAGSS_00110339		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3653		Medical records	OKAGSS_00110340	OKAGSS_00110368		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3654		Medical records	OKAGSS_00180747	OKAGSS_00180788		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3655		Medical records	OKAGSS_00180975	OKAGSS_00181078		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3656		Medical records	OKAGSS_00181684	OKAGSS_00181759		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3657		N. Gajraj, Letter to the Editor: Opiate Abuse or Undertreatment, The Clinical Journal of Pain (Mar. 1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3658		P. Delleijm, "Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain," 16 Journal of Pain and Symptom Management 220 (1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3659		P. Koke, "Human Immunodeficiency Virus 1 Envelope Proteins Induce Interleukin 1, Tumor Necrosis Factor $\alpha$ , and Nitric Oxide in Glial Cultures Derived from Fetal, Neonatal, and Adult Human Brain," 182 J. Exp. Med. 941 (1995)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3660		P. Nelson, "Developing an Intervention to Alter Catastrophizing in Persons with Fibromyalgia," Orthopaedic Nursing (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3661		Preface to the First Edition, Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3662		Prescribe Responsibly Website Printout, www.prescriberesponsibly.com (visited Nov. 2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3663		Press Release: Health Professionals for Patients in Pain, Professionals Call on the CDC to Address Misapplication of its Guideline on Opioids for Chronic Pain through Clarification and Impact Evaluation, Mar. 6, 2009				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3664		PriCara, Smart Moves, Smart Choices: A Prescription Drug Abuse Education Program, Oct. 27, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3665		R. Brown, "Conjoint Screening Questionnaires for Alcohol and Other Drug Abuse: Criterion Validity in a Primary Care Practice," Wisconsin Medical Journal (1995)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3666		R. Buynak, "Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo and active-controlled Phase III study," 11 Expert Opin. Pharmacother. 1787 (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3667		R. Chou, "Opioid Treatment Guidelines," 10 Journal of Pain 113 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3668		R. Dart, "Diversion and Illicit Sale of Extended Release Tapentadol In the United States," 17 Pain Medicine 1490 (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3669		R. Dart, "Nonmedical Use of Tapentadol Immediate Release by College Students," 30 Clin J Pain 685 (2014)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3670		R. Dworkin, "Pharmacologic Management of Neuropathic Pain: Evidence-Based Recommendations," 132 Pain 237 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3671		R. Edwards, "Genetic Predictors of Acute and Chronic Pain," in Rheumatic Manifestations of Other Diseases (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3672		R. Galvez, "Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study," 30 Adv Ther 229 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3673		R. Libby, "Treating Doctors as Drug Dealers The DEA's War on Prescription Painkillers," Policy Analysis (June 1, 2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J3674		R. Marks, "Undertreatment of Medical Inpatients with Narcotic Analgesics," 78 Annals of Internal Medicine 173 (1973)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3675		R. Metzack, "Pain Mechanisms: A New Theory," 150 Science 972 (1965)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3676		R. Nahlin, "Estimates of Pain Prevalence and Severity in Adults: United States, 2012," 16 Journal of Pain 769 (2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3677		R. Portenoy, "Chapter 55: Acute and Chronic Pain," in Substance Abuse: A Comprehensive Textbook (2005, 4th ed.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3678		R. Raffa, "Pharmacological aspects of successful long-term analgesia," 25 Clinical Rheumatology (Supp. 1) S9 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3679		R. Simpson, "Transdermal Fentanyl as Treatment for Chronic Low Back Pain," 14 Journal of Pain & Symptom Management 218 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3680		R.J. Mannion, "Neurotrophins: Peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity," 96 Neurobiology 9385 (1999)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3681		Response to Sept. 7, 2004 Letter (Sept. 17, 2004) (JAN-MS-00291332)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3682		Rough Transcript of Deposition of J. Beaman, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 26 & 27, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3683		R-R Ji, "p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia," 36 Neuron 57 (2002)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3684		S. Butler, "Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment," 16 Pain Medicine 119 (2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3685		S. Fishman, "The Opioid Contract in the Management of Chronic Pain," 18 Journal of Pain and Symptom Management 27 (1999)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3686		S. Fishman, The War on Pain: How Breakthroughs in the New Field of Pain Medicine Are Turning the Tide Against Suffering 5-25 (2000)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3687		S. Macres, "Adjuvant Analgesics" in Principles and Practice of Pain Medicine (2d ed., 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3688		S. Passik, "A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy," Clinical Therapeutics (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3689		S. Passik, "Addiction-Related Assessment Tools and Pain Management: Instruments for Screening, Treatment Planning, and Monitoring Compliance," 9 Pain Medicine S146 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3690		S. Passik, "An Opioid Screening Instrument: Long-Term Evaluation of the Utility of the Pain Medication Questionnaire by Holmes et al.," Pain Practice (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3691		S. Passik, "Current Risk Assessment and Management Paradigms: Snapshots in the Life of the Pain Specialist," Pain Medicine (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3692		S. Passik, "Monitoring Outcomes During Long-Term Opioid Therapy for Noncancer Pain: Results with the Pain Assessment and Documentation Tool," Journal of Opioid Management (2005)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3693		S. Passik, "Pseudoaddiction revisited: a commentary on clinical and historical considerations," Pain Management (2011)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3694		S. Passik, "Substance Abuse Issues in Cancer Patients," Oncology (Apr. 1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3695		S. Proctor, "Prevalence of Substance Use and Psychiatric Disorders in a Highly Select Chronic Pain Population," 7 Journal of Addictive Medicine 17 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3696		S. Pyati, "Perioperative Pain Management," 21 CNS Drugs 185 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3697		S. Schwartz, "Safety and Efficacy of Tapentadol ER in Patients with Painful Diabetic Peripheral Neuropathy: Results of a Randomized-Withdrawal, Placebo-Controlled Trial," 27 Current Medical Research & Opinion 151 (2011)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3698		S. Stanos, "Pain Management with Opioid Analgesics Balancing Risk & Benefit," 88 Am. J. Phys. Med. Rehabil. S69 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3699		S. Stonington, "Structural Inotropogenesis — A 43-Year-Old Man with 'Opioid Misuse,'" 380 New England Journal of Medicine 701 (2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3700		S. Vesce, "HIV-1 gpl20 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid," 411 FEBS Letters 107 (1997)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3701		S.M. Fleetwood-Walker, "Antinociceptive Actions of Descending Dopaminergic Tracts on Cat and Rat Dorsal Horn Somatosensory Neurons," 399 Journal of Physiology 335 (1988)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3702		Slide Presentation, "Neo Pathways - What Every Physician Should Know About Pain"	JAN-MS-00472750			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3703		Smart Moves, Smart Choices Teen Prescription (Rx) Drug Abuse Awareness, School Tool Kit	JAN-MS-00895579			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3704		Smart Moves, Smart Choices, A Prescription Drug Abuse Education Program Presentation, Program Success and Looking Ahead, PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Oct. 27, 2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3705		Tapentadol ER: Clinical Overview	JAN-MS-00214445			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3706		Tapentadol IR: MODULE 2.5 - Clinical Overview	JAN-MS-00230459			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3707		Admissions to ODMHSAS Funded Substance abuse Treatment by Drug of Choice and County of Residence (Ages 12+), ODMHSAS Online Query System (OOnQues)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3708		Oklahoma Department of Mental Health and Substance Abuse Services presentation, Mental Illness and Addiction: A community Concern				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3709		Oklahoma Tobacco Settlement Endowment Trust, FY18 Annual Report				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3710		Alice Asher, et al., Estimating the Cost of a Comprehensive Syringe Services Program in the United States				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3711		Oklahoma Bureau of Narcotics Presentation: Drugs of Abuse: The Elephant in the Room				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3712		Oklahoma Bureau of Narcotics Presentation: Drugs of Abuse: A Dose of Reality				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3713		Oklahoma Bureau of Narcotics Presentation: Drug Trends, Trojan Horse, and The Elephant in the Room!				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3714		Oklahoma Bureau of Narcotics Presentation: Understanding Medical Marijuana and the Opioid Crisis				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3715		Oklahoma Bureau of Narcotics Presentation: Drug Trends, Trojan Horse, and The Elephant in the Room!				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3716		ODMHSAS Online Query System Admissions to Treatment 2012 to 2018 (By Drug of Choice and County of Residence)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3717		Video: Terri White: Painkiller Addiction				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3718		Video: Prescription Drugs: Terri White discusses Oklahoma's ranking in recent CDC report				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3719		Video: Addiction Summit: Issues facing Oklahoma				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3720		All pleadings filed by any party in this case.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3721		All discovery responses by any party in this case.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3722		All documents produced in discovery, not otherwise objected to by Janssen.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3723		All deposition exhibits, not otherwise objected to by Janssen.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3724		All nonobjectionable materials identified as trial exhibits in the State's May 6, 2019 Proposed Exhibit List and any amendment thereto.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3725		All documents or other material relied upon by any expert witness.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3726		Any exhibit needed for rebuttal and/or impeachment by Janssen.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3727		Demonstrative aids, graphics, and summaries of financial data.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3728		All nonobjectionable materials identified as trial exhibits in Defendants Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc., f/k/a Watson Pharma, Inc.'s May 6, 2019 Exhibit List and any amendment thereto.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3729	02/19/2019	McAllister Deposition Notice			McAllister (2019.03.19) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3730	12/21/2018	Ex. N - Dr. William McAllister, Ph.D. of State's Expert Witness Disclosures					
J3731	04/08/2019	Sooner Care DHCA Letter, Opioid Analgesic Morphine Milligram Equivalents (MME) Limits				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3732	02/27/2019	OKC Fox News, M. Scavelli, OKCPD Make 2nd Largest Fentanyl Bust in Oklahoma History				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3733	07/05/2011	Report of Investigation by Medical Examiner - Austin Box			Box (03.15.2019) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3734	06/01/2008	Dear Doctor Letter re New Prescribing and Dispensing Information for Duragesic	JAN-MS-00291141	JAN-MS-00291141		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3735	03/01/2013	Dear Doctor Letter re Important Change in Duragesic for Transdermal Administration CII, Complete Prescribing Information	JAN-MS-03945918	JAN-MS-03945921		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3736	08/25/2011	Nucynta ER NDA Approval Letter from FDA	JAN-MS-02558181	JAN-MS-02558288		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3737	2002	Inspector General's Final Report, Review of the DEA's Investigations of the Diversion Controlled Pharmaceuticals, Report No. I-2002-010				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3738	01/31/2019	KOLD News 13, CBP Seizes Record-Breaking Amount of Fentanyl				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3739	02/08/2019	Tulsaworld.com, Tulsa Woman Signs for \$2 million Worth of Fentanyl in Package Delivery Drug Bust, Sheriff's Office Says				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3740	09/01/2011	AP Article - Sooners, Family Search for Answers to Austin Box's Death			Box (03.15.2019) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3741	2008	Nature Education - Genetic Mutation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3742	2008	DEA Form 225 - Application for Registration Under the Controlled Substances Act				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3743	6/00/2005	Dear Doctor Letter re Changes to Duragesic Prescribing Information	JAN-MS-00683408	JAN-MS-00683412		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3744	8/25/2011	Dear Doctor Letter re Risk of Potential Abuse, Misuse, Overdose, and Addiction for Nucynta ER	JAN-MS-01476308	JAN-MS-01476311		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3745	6/00/2012	Dear Doctor Letter re Announcement of REMS	JAN-MS-01461550	JAN-MS-01461551		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3746		National IMS Data	JAN-MS-03108026			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3747		OKHCA Quantity Limits - Analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3748	01/01/2010	Nucynta Visual Aid	JAN-MS-00136198			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3749		NewsOK, Addicted Oklahoma: Profiting from Pain			Woodward Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3750		About OBNDD			Stewart (01.22.2019) Ex. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3751		Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances	OBN-00034233	OBN-00034250	Stewart (01.22.2019) Ex. 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3752		OBN, Drug Diversion and the PMP			Stewart (01.22.2019) Ex. 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3753		Action Chart			Stewart (01.22.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3754	05/21/2013	Pinney Associates, Implications for Nucynta IR	JAN-MS-00604220	JAN-MS-00604248		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3755		Diversion and Illicit Sale of Extended-Release Tapentadol in the United States	JAN-MS-05365400	JAN-MS-05365400		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3756		RADARS System Overview	JAN-MS-02296262	JAN-MS-02296313		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3757	12/02/2014	Email from Amanda Zanetti to Kerri Wade, OK Supplemental Rebates	OHCA-00110451	OHCA-00110455	Beasley Ex. 35	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3758	2017	2017 Oklahoma Drug Threat Assessment Powerpoint	OBN-00238633			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3759	2018	Oklahoma Drug Threat Assessment Presentation	OBN-00238640			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3760	06/19/2009	Letter re Submission of IND for Nucynta ER	JAN-MS-002200676	JAN-MS-002200678		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3761	2010-2015	IMS Sales Data for Janssen - Oklahoma	JAN-OK-00145267	JAN-OK-00145269		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3762	02/01/1973	R. Marks & E. Sachar, Annals of Internal Medicine, Undertreatment of Medical Inpatients with Narcotic Analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3763		R. Twycross, The Use of Narcotic Analgesics in Terminal Illness				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3764		M. Meldrum, A Capsule History of Pain Management, Am. Medical Assoc.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3765		Nucynta 21st Century Technology Presentation	JAN-MS-02319887			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3766	2006-2014	Confidential DEA ARCOS Data				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3767		M. Laurentius Marais Analysis of DEA ARCOS Data				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3768	01/07/2008	Duragesic Dosage Guide	JAN-MS-01997111			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3769		Dear Healthcare Professional Letter	JAN-MS-00591645			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3770		OBND, About OBND			Edminsten (03.12.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3771		Title 63 of Oklahoma Statutes, Section 2-205			Edminsten (03.12.2019) Ex. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3772	08/29/2005	August 29, 2005 Letter from Mahoney			McGuire (2018.12.14) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3773	10/12/2006	Excerpts from 2006 Update			McGuire (2018.12.14) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3774	11/15/2018	November 2018 MAC Agenda and Minutes			Crawford (2019.02.13) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3775	03/09/2017	March 2017 MAC Agenda and Minutes			Crawford (2019.02.13) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3776	01/19/2016	January 2016 MAC Agenda and Minutes			Crawford (2019.02.13) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3777	10/20/2014	November 2014 MAC Agenda and Minutes			Crawford (2019.02.13) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3778	08/08/2015	Chronic Opioid Analgesic Therapy for Chronic Low Back Pain			Crawford (2019.02.13) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3779		2010 Amendment to Supply Agreement between Noramco and Teva	TEVA_OK_05035391			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3780		2004 Supply Agreement between Noramco and Amide	TEVA_OK_05040500			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3781		2008 Supply Agreement between Cephalon and Mallinckrodt	TEVA_OK_05046558			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J3782		2009 Amended and Restated Supply Agreement between Cephalon and Mallinckrodt	TEVA_OK_0504660 6			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3783		2012 Amendment No 1 to Amended and Restated Agreement between Cephalon and Mallinckrodt	TEVA_OK_0504659 1			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3784		2009 Supply Agreement between Noramco and Actavis Elizabeth LLC	TEVA_OK_0505438 0			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3785		2015 Supply Agreement between Actavis, Inc. and Noramco	TEVA_OK_0505555 0			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3786		2006 API Supply Agreement between Anesta and Johnson Matthey	TEVA_OK_0504008 0			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3787		2009 Supply Agreement between Teva and Johnson Matthey	TEVA_OK_0505938 7			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3788		2010 Manufacturing and Supply Agreement between Siegfried and Plantex	TEVA_OK_0506255 3			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3789		2012 Supply Agreement between Johnson Matthey and Teva	TEVA_OK_0507017 1			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3790		2011 API Supply Agreement between Watson Labs and Johnson Matthey	TEVA_OK_0332399 4			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	H; AU; R; 2402; 2403; LF; CON
J3791		Email from Gary Baker to Sarah Chamberlain and Gary Vorsanger	JAN-MS-02057424			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3792		Totality Closeout Documentation	JAN-MS-02057427			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3793		Next Steps Key Slides	JAN-MS-02057430			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3794		Meeting #2 Slide Deck	JAN-MS-02057431			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3795		February 2012 Meeting Summary Slides	JAN-MS-02057432			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3796	05/04/2012	May 4, 2012 Meeting Output	JAN-MS-02057433			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3797		Manuscript Draft	JAN-MS-02057434			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3798		AH Vallerand, P Cosler, JE Henningfield, P Galassini. Pain management strategies and lessons from the military: A narrative review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3799	05/06/2019	Pain Management Best Practices Inter-Agency Task Force Report				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3800	02/12/2019	LinkedIn Profile of Shellee Keast			Keast, 2/12/19, No. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3801	02/12/2019	OU Health Sciences Center webpage for Shellee Keast			Keast, 2/12/19, No. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3802	02/12/2019	Controlled Substances Act from DOJ website			Keast, 2/12/19, No. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3803	03/04/2004	DUR Board Meeting Packet			Keast, 2/12/19, No. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3804	04/08/2004	DUR Board Meeting Packet			Keast, 2/12/19, No. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3805	10/06/2004	DUR Board Meeting Packet			Keast, 2/12/19, No. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3806	11/04/2004	DUR Board Meeting Packet			Keast, 2/12/19, No. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3807	12/08/2014	Keast's article "Strategies aimed at controlling misuse and abuse ..."			Keast, 2/12/19, No. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3808	10/27/2014	SoonerCare bulletin re: No More Than 4 campaign			Keast, 2/12/19, No. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3809	02/07/2013	DUR Board Meeting Packet			Keast, 2/12/19, No. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3810	04/12/2006	DUR Board Meeting Packet			Keast, 2/12/19, No. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3811	01/06/2005	DUR Board Meeting Packet			Keast, 2/12/19, No. 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3812	02/07/2018	Email from K. Egesdal to N. Nesser, B. Holderread, and B. Beasley re: ADURS: use of prospective DUR alerts to address concurrent use of opioids and benzos			Keast, 2/12/19, No. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3813	07/12/2017	DUR Board Meeting Packet			Keast, 2/12/19, No. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3814	04/29/2016	Email from B. Beasley to K. Egesdal, B. Holderread, and N. Nesser re: More than one opioid			Keast, 2/12/19, No. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3815	09/05/2014	Email from S. Keast to N. Nesser re: Added a Paragraph			Keast, 2/12/19, No. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3816	09/13/2018	DUR Board Meeting Packet			Keast, 2/12/19, No. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3817	02/12/2019	DUR Board statutes, Okla. Admin. Code 5030.1 et seq.			Keast, 2/12/19, No. 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3818	02/12/2019	HCA medical necessity statute, Okla. Admin. Code 317:30-3-1			Keast, 2/12/19, No. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3819	08/18/2019	Article with Keast as co-author: "Overview of Prescription Opioid Deaths ..."			Keast, 2/12/19, No. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3820	09/06/2018	News article re: "Purdue Pharma L.P. to present data from three research studies at PAINWeek 2018 annual conference"			Keast, 2/12/19, No. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3821	04/09/2018	Keast's article "Effects of a prior authorization policy ..."			Keast, 2/12/19, No. 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3822	08/15/2016	SoonerCare bulletin re: Brand Name OxyContin Preferred Over Generic			Keast, 2/12/19, No. 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3823	n/a	Prior Authorization statute, Okla. Admin. Code 317:30-3-31				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3824	10/26/2015	Oct. 26-27, 2015 Email Chain Between Byron Curtis, Timothy Dwyer, and others	OCME-00092481			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3825	11/24/2015	Nov. 24-30, 2015 Email Chain Between Byron Curtis and Claire Nguyen	OCME-00092583			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3826	8/8/2014	August 8-25, 2014 Email Chain Between Byron Curtis and Sarah Willhour	OCME-00090878			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3827	2018	Byron Curtis Notice of Deposition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3828	2015	2015 Office of the Chief Medical Examiner Annual Report				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3829	2014	2014 Office of the Chief Medical Examiner Annual Report				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3830	2013	2013 Office of the Chief Medical Examiner Annual Report	OCME-00000739			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3831	2012	2012 Office of the Chief Medical Examiner Annual Report	OCME-00000691			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3832	2011	2011 Office of the Chief Medical Examiner Annual Report	OCME-00000589			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3833	2009	2009 Office of the Chief Medical Examiner Annual Report	OCME-00000317			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3834	2008	2008 Office of the Chief Medical Examiner Annual Report	OCME-00000231			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J3835	2007	2007 Office of the Chief Medical Examiner Annual Report	OCME-00000123			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3836	2006	2006 Office of the Chief Medical Examiner Annual Report	OCME-00000001			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3837	2005	2005 Office of the Chief Medical Examiner Annual Report	OCME-00089439			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3838	2004	2004 Office of the Chief Medical Examiner Annual Report	OCME-00089357			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3839	2003	2003 Office of the Chief Medical Examiner Annual Report	OCME-00089285			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3840	2010	2010 Office of the Chief Medical Examiner Annual Report			Curtis Dep. Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3841	10/20/2013	Oct. 20, 2013 Email Chain Between Byron Curtis and Hyesu Grace Kim	OCME-00088872		Curtis Dep. Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3842	11/23/2015	Nov. 23, 2015 Email Seemingly Between Byron Curtis and Himself	OCME-00092559		Curtis Dep. Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3843	11/20/2015	Nov. 20, 2015 Email Between Byron Curtis and Himself	OCME-00092558		Curtis Dep. Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3844	03/21/2017	Mar. 21, 2017 Email Chain Between Byron Curtis and Eric Pfeifer	OCME-00086524		Curtis Dep. Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3845	03/11/2015	Mar. 11, 2015 Email and Attachment with Presentation (Overdose Death Investigation Procedures: Determining Manner and Cause, and Toxicology Testing)	OCME-00091367		Curtis Dep. Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3846		Laboratory Services and Pricing for External Requests	OCME-00092504		Curtis Dep. Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3847	06/19/2017	June 19-20, 2017 Email Chain Between Byron Curtis, Jesse Kemp, and Ross Miller	OCME-00086985		Curtis Dep. Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3848	02/17/2015	Feb. 17, 2015 Email Between Timothy Dwyer and Sheryll Brown with Attachment Flyer and Questions for Medical Examiner Training	OCME-00091279		Curtis Dep. Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3849	08/17/2017	Aug. 17, 2017 Email Chain Between Matt Stillwell and Byron Curtis	OCME-00087200		Curtis Dep. Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3850	2017	2017 Office of the Chief Medical Examiner Annual Report			Curtis Dep. Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3851	2016	2016 Office of the Chief Medical Examiner Annual Report			Pfeifer Dep. Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3852	4/15/2008	Purdue Quarterly Report to the Board	PDD8901724434			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3853		Timeline of Events for the Oklahoma Opioid Prescribing Guidelines			Herndon (01.25.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3854		Office-Based Acute Guidelines			Herndon (01.25.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3855		Office-Based Chronic Guidelines			Herndon (01.25.2019) Ex. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3856	04/21/2014	Email Chain Between Mike Herndon, Dianne Hasselman and Catherine Brock - Subject: RE: Question	OHCA-00116821		Herndon (02.22.2019) Ex. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3857	08/13/2015	Article from The Oklahoman "Prescription Drug Abuse Continues to Plague Oklahoma"			Herndon (02.22.2019) Ex. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3858		Charles Eckman verified complaint			Herndon (03.14.2019) Ex. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3859		William Kerry Smith verified complaint			Herndon (03.14.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3860	03/04/2015	Email	OHCA-00007202	OHCA-00007204	Cothran (02.27.2019) Ex. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3861	09/13/2018	Memorandum, OU College of Pharmacy, Pharmacy Management Consultants			Cothran (02.27.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3862		OHCA SoonerCare, Opioid Analgesic Quantity Limits - No More than 4	OHCA-00005365		Cothran (02.27.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3863	01/18/2018	Email	OHCA-00001880	OHCA-00001882	Cothran (02.27.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3864	06/13/2014	Email	OHCA-00003250	OHCA-00003253	Cothran (02.27.2019) Ex. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3865		Clinical Decision Support Quantity Limit Edits			Holderread (02.08.2019) Ex. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3866	06/13/2007	Drug Utilization Review Board Committee Minutes			Holderread (02.08.2019) Ex. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3867		Email String Re: "More Than One Opioid"			Holderread (02.08.2019) Ex. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3868		4/29/16 E-mail, OHCA-00081295-81296			Egesdal, Karen (03.05.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3869		7/7/17 E-mail, OHCA-00102565-102568			Egesdal, Karen (03.05.2019) Ex. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3870			OHCA-00445510		Egesdal, Karen (03.05.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3871	10/12/2004	OHCA DURB Meeting Minutes	OKAG-00012707	OKAG-00012711	Egesdal, Karen (03.05.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3872	05/16/2014	Email	OHCA-00157869	OHCA-00157870	Egesdal, Karen (03.05.2019) Ex. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3873	02/03/2012	Email	OHCA-00096507	OHCA-00096510	Egesdal, Karen (03.05.2019) Ex. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3874	07/25/2018	Email	OHCA-00423043	OHCA-00423050	Egesdal, Karen (03.05.2019) Ex. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3875	2015	Quality Team Day 2015 Project Application, OHCA-00334448-334450	OHCA-00334448	OHCA-00334450	Egesdal, Karen (03.05.2019) Ex. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3876	07/01/2003	OHCA Paid Pharmacy Claims, July 1, 2003 - June 30, 2004	OKAG-00008572	OKAG-00008574	Egesdal, Karen (03.05.2019) Ex. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3877		OHCA Paid Pharmacy Claims, July 1, 2001 - June 30, 2005	OKAG-00006212	OKAG-00006226	Egesdal, Karen (03.05.2019) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3878		Top 50 Medications by Claims	OKAG-00000520	OKAG-00000521	Egesdal, Karen (03.05.2019) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3879		Top 50 Medications by Claims, Fiscal Year 2010	OKAG-00013838	OKAG-00013839	Egesdal, Karen (03.05.2019) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3880		Top 50 Medications by Claims, Fiscal Year 2011	OKAG-00013665	OKAG-00013666	Egesdal, Karen (03.05.2019) Ex. 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3881		Top 50 Medications by Claims, Fiscal Year 2013	OKAG-00011455	OKAG-00011456	Egesdal, Karen (03.05.2019) Ex. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3882		Top 50 Medications by Claims, Fiscal Year 2014	OKAG-00011578	OKAG-00011579	Egesdal, Karen (03.05.2019) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3883		Top 50 Medications by Claims, Fiscal Year 2015	OKAG-00008405	OKAG-00008406	Egesdal, Karen (03.05.2019) Ex. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3884	02/07/2018	Email	OHCA-00002099	OHCA-00002100	Egesdal, Karen (03.05.2019) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3885		Concomitant Benzodiazepine and Opioid Utilization	OKAG-00010826	OKAG-00010829	Egesdal, Karen (03.05.2019) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3886		Incomplete Draft Response to 2005 FDA Letter re IONSYS	JAN-MS-02136847	JAN-MS-02136851		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3887		Email exchange between Terry Cothran, Bethany Holderread, and John Muchmore			Muchmore Ex. 70	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3888	01/25/2017	The Shawnee News-Star: White shares mental health data				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3889	2012-2018	ODMHSAS Admissions to Treatment Online Query System (Any Drug of Choice)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3890		Report of Investigation			Pfiefer (01.09.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3891		Email dated 2-11-2015 from B. Curtis to T. Dwyer			Pfiefer (01.09.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3892		"Fatal Unintentional Poisoning Surveillance System Data Update"			Pfiefer (01.09.2019) Ex. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3893		2018 Abridged Formulary, Silverscript			Lawler (02.20.2019) Ex. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3894	02/19/2019	Fraud, Waste and Abuse Compliance			Lawler (02.20.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3895	01/01/2018	Healthchoice, Administrative Rules			Lawler (02.20.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3896		Organizational Responsibility of Medical Services			McCurdy (12.13.2018) Ex. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3897		Oklahoma Association for Justice news article			Geiger (03.29.2019) Ex. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3898		OMES website printout			Geiger (03.29.2019) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3899		OpenBooks - Oklahoma's Finances: Online & in Action			Geiger (03.29.2019) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3900		The State of Oklahoma Comprehensive Annual Finance Report 2018			Geiger (03.29.2019) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3901		State of Oklahoma Executive Budget Fiscal Year 2017			Geiger (03.29.2019) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3902		Budget Justification, Oklahoma Prescription Drug Overdose Prescription Program, Funding Opportunity Announcement			Geiger (03.29.2019) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3903		Injury Prevention Service Grant Information August 2017			Geiger (03.29.2019) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3904		"Let's Talk Pain" Survey results	JAN-MS-00500229			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3905		Let's Talk Pain Survey Messages	JAN-MS-00500231			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3906		Utilization Controls for Narcotic Analgesics in the SoonerCare Program			Beasley, B. (02.11.2019) Ex. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3907		Okl. Admin. Code 317:30-3-1			Beasley, B. (02.11.2019) Ex. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3908	08/15/2016	SoonerCare - Brand Name OxyContin Preferred Over Generic			Beasley, B. (02.11.2019) Ex. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3909		OHCA Website Printoff "About Us"			Beasley (02.12.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3910		Oklahoma Administrative Code 317:30-5-86 Drug Utilization Review Program			Beasley (02.12.2019) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3911		Drug Utilization Review Board Printout from OHCA Website			Beasley (02.12.2019) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3912		Oklahoma Administrative Code 317:30-5-77.2 Prior Authorization			Beasley (02.12.2019) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J3913		Oklahoma Administrative Code 317:30-5-77.3 Product-Based Prior Authorization			Beasley (02.12.2019) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3914	04/09/2008	DURB Meeting Packet			Beasley (03.1.2019) Ex. 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3915		Multiple Prescriber Episodes 1Q2014-3Q2018			Beasley (03.1.2019) Ex. 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3916	11/07/2016	"Dear SoonerCare Provider"			Beasley (03.1.2019) Ex. 37	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3917	11/19/2018	SoonerCare "Dear Pharmacist" Letter			Beasley (03.1.2019) Ex. 39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3918		Email String Re: Mortality Data Review Rx Drug Overdose			Beasley (03.1.2019) Ex. 45	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3919		63 Okl. St. 5053.1			Beasley (03.1.2019) Ex. 46	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3920		Email String Re: Dr. Laski Being Interviewed by Channel 12 Following the Newsweek Article			Beasley (03.1.2019) Ex. 47	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3921	05/17/2019	EGID data production				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3922		Photographs from reports and summaries produced by the Office of the Chief Medical Examiner				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3923		All reports and communications EGID has received from or sent to pharmacy benefit managers produced in this litigation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J3924		Supplement: 80 Additional OCME Deaths 2012-2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

# EXHIBIT F

Exhibit No.	Bates No.	Description	State's Objections	J.&J and Janssen's objections (J.&J and Janssen reserve the right to object at trial to any Teva exhibit because J.&J and Janssen have not had the opportunity to review them)
1000	OBN-60174- OBN-60181	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1001	OKMB-6246- OKMB-6252	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1002	OSBOE-567- OSBOE-570	Findings of Fact, Conclusion of Law and Emergency Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1003	OKMB-6263- OKMB-6268	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1004	OBN-60204- OBN-60219	Immediate Suspension of OBNDD Registration	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1005	OSBOE-3273- OSBOE-3285	Finding of Fact, Conclusions of Law and Agreed Order of Monitoring	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1006	OSBOE-3286- OSBOE-3290	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1007	OSBOE-510- OSBOE-517	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1008	OKMB-4509- OKMB-4522	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1009	OSBOE-531- OSBOE-535	Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1010	OKMB-12965- OKMB-12975	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1011	OBD-8229- OBD-8236	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1012	OKMB-7991- OKMB-7993	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1013	OKMB-7994- OKMB-7995	Agreed Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1014	OSBOE-550- OSBOE-554	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1015	OBD-8311- OBD-8318	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1016	OBN-60160- OBN-60162	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1017	OBD-8319- OBD-8325	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1018	OBN-60252- OBN-60264	Notice of Hearing and Order to Show Cause	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1019	OBN-60280- OBN-60281	Order Staying Proceedings	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1020	OSBOE-592- OSBOE-596	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1021	OSBOE-4581- OSBOE-4583	Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1022	OBD-8353- OBD-8355	Findings of Fact, Conclusions of Law and Order of Suspension and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1023	OBD-8356- OBD-8358	Agreed Order to Summarily Suspend License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1024	OSBOE-608- OSBOE-614	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1025	OKMB-8019- OKMB-8027	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1026	OBN-60163- OBN-60165	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1027	OSBOE-254- OOSBOE-2551	Interim Order of Suspension With Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1028	OSBOE-2552- OSBOE-2557	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1029	OKMB-36198- OKMB-36208	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1030	OBN-60102- OBN-60104	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1031	OSBOE-635- OSBOE-641	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1032	OBN-60290- OBN-60296	Stipulation and Agreed Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1033	OKMB-36540- OKMB-36549	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1034	OKMB-36209- OKMB-36217	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1035	OKMB-36218- OKMB-36224	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1036	OKMB-6420- OKMB-6424	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1037	OSBOE-664- OSBOE-667	Findings of Fact, Conclusions of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1038	OSBOE-671- OSBOE-679	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1039	OBD-8453- OBD-8460	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1040	OKMB-8039- OKMB-8048	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1041	OKMB-6433- OKMB-6437	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1042	OKMB-6444- OKMB-6446	Order Accepting Voluntary Surrender of License in Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1043	OKMB-11630- OKMB-11641	Order Accepting Voluntary Surrender of License in Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teya exhibit because J&J and Janssen have not had the opportunity to review them)
1044	OKMB-6452- OKMB-6454	Order of Emergency Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1045	OKMB-6482- OKMB-6487	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1046	OBD-8492- OBD-8498	Agreed Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1047	OKMB-6501- OKMB-6507	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1048	OSBOE-680- OSBOE-683	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1049	OSBOE-684- OSBOE-698	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1050	OSBOE-1970- OSBOE-1974	Order With Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1051	OSBOE-1975- OSBOE-1978	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1052	OKMB-8057- OKMB-8060	Verified Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1053	OKMB-8066- OKMB-8075	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1054	OKMB-36225- OKMB-36232	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	



Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1055	OKMB-4586- OKMB-4595	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1056	OKMB-6580- OKMB-6583	Final Order of Reprimand	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1057	OSBOE-4506- OSBOE-4510	Order of Suspension With Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1058	OSBOE-4511- OSBOE-4514	Findings of Fact, Conclusions of Law and Emergency Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1059	OSBOE-4515- OSBOE-4518	Emergency Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1060	OKMB-8567- OKMB-8579	Order of Suspension of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1061	OKMB-13204- OKMB-13207	Voluntary Surrender of License in Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1062	OBN-60166- OBN-60170	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1063	OBD-8646- OBD-8650	Agreed Order of Probation –	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1064	OBD-8661- OBD-8664	Agreed Order of Suspension and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1065	OKMB-6607- OKMB-6612	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1066	OSBOE-2823- OSBOE-2826	Order of Probation With Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1067	OSBOE-2827- OSBOE-2833	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1068	OSBOE-2627- OSBOE-2642	Findings of Fact, Conclusions of Law and Agreed Order of Monitoring	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1069	OSBOE-3771- OSBOE-3775	Findings of Fact, Conclusions of Law and Agreed Order of Monitoring	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1070	OSBOE-725	Affidavit for Surrender of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1071	OSBOE-727- OSBOE-729	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1072	OKMB-13247- OKMB-13251	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1073	OKMB-4815- OKMB-4821	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1074	OKMB-4808- OKMB-4814	Final Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1075	OSBOE-1060- OSBOE-1063	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1076	OSBOE-1074- OSBOE-1075	Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1077	OSBOE-1076- OSBOE-1081	Findings of Fact, Conclusions of Law and Emergency Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1078	OSBOE-1082- OSBOE-1095	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1079	OSBOE-1101- OSBOE-1105	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1080	OSBOE-1100	Affidavit of Retirement	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1081	OKMB-8753- OKMB-8757	Voluntary Surrender of License in Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1082	OSBOE-1195- OSBOE-1200	Findings of Fact, Conclusions of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1083	OSBOE-1210- OSBOE-1215	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1084	OBD-8722- OBD-8724	Agreed Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1085	OKMB-4826- OKMB-4832	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1086	OKMB-6715- OKMB-6721	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1087	OKMB-8840- OKMB-8845	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1088	OKMB-8887- OKMB-8891	Voluntary Surrender of License in Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1089	OKMB-17913- OKMB-17914	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1090	OKMB-6772- OKMB-6775	Order of the Board Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1091	OBN-60391- OBN-60393	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1092	OBN-60401- OBN-60407	Amended Order to Show Cause & Notice of Hearing	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1093	OBN-60409- OBN-60410	Voluntary Surrender of Controlled Dangerous Substances Registration	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1094	OKMB-4852- OKMB-4858	Verified Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1095	Order is not bates labeled	Order of Revocation of Medical License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1096	OKMB-8945- OKMB-8949	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1097	OKMB-6807- OKMB-6812	Amended Final Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1098	OKMB-3170- OKMB-3178	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teya exhibit because J&J and Janssen have not had the opportunity to review them)
11099	OKMB-4916- OKMB-4924	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11100	OKMB-4945- OKMB-4952	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11101	OSBOE-5045- OSBOE-5049	Finding of Fact, Conclusion of Law And Agreed Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11102	OSBOE-5050- OSBOE-5053	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11103	OKMB-6921- OKMB-6926	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11104	OKMB-8970- OKMB-8978	Order of Revocation of License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11105	OSBOE-755- OSBOE-758	Finding of Fact, Conclusion of Law And Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11106	OSBOE-759- OSBOE-781	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11107	OSBOE-789- OSBOE-792	Emergency Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11108	OSBOE-794- OSBOE-795	Preceptor Plan	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
11109	OSBOE-787- OSBOE-788	Order of Preceptorship	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1110	OBN-61939- OBN-61941	Stipulation and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1111	OBN-61942- OBN-61971-	Immediate Suspension Due To Imminent Danger	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1112	OKMB-21209- OKMB-21272	Amended Order for Immediate Summary Suspension of Probationary License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1113	OSBOE-2591- OSBOE-2595	Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1114	OSBOE-2596- OSBOE-2599	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1115	OSBOE-1178- OSBOE-1182	Finding of Fact, Conclusion of Law And Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1116	OKMB-6943- OKMB-6951	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1117	OSBOE-1323-OSBOE-1326- 1331--OSBOE-1339-OSBOE-1344	Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1118	OSBOE-1327- OSBOE-1331	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1119	OSBOE-1339- OSBOE-1344	Stipulation of Facts	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1120	OBD-8963- OBD-8965	Agreed Order of Probation and Administrative Penalty	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1121	OKMB-9567- OKMB-9592	Verified Complaint	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1122	OKMB-9600- OKMB-9605	Order Granting Restricted License Under Terms of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1123	OKMB-9642- OKMB-9655	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1124	OKMB-9662- OKMB-9668	Verified Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1125	OKMB-5153- OKMB-5159	Order of Suspension of Medical License and Restrictions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1126	OKMB-5167- OKMB-5171	Final Order of Revocation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1127	OKMB-5177- OKMB-5181	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1128	OKMB-5197- OKMB-5210	Order Accepting Voluntary Submission to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1129	OKMB-5211- OKMB-5218	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1130	OKMB-5222- OKMB-5236	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1131	OKMB-5246- OKMB-5253	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1132	OBN-60415- OBN-60418	Immediate Suspension Due to Imminent Danger	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1133	OBD-9006- OBD-9008	Agreed Order of Voluntary Surrender	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1134	OBD-9080- OBD-9084	Proposed Agreed Order of Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1135	OKMB-9870- OKMB-9877	Voluntary Surrender of License In Lieu of Prosecution With Waiver of Right to Reapply	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1136	OBD-9169- OBD-9174	Agreed Order of Suspension and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1137	OBD-9195- OBD-9197	Consent Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1138	OKMB-17000- OKMB-17009	Order of Suspension of Medical License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1139	OKMB-7050- OKMB-7059	Final Order of Suspension	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1140	OSBOE-1221- OSBOE-1235	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1141	OSBOE-1216- OSBOE-1220	Finding of Fact, Conclusion of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1142	OSBOE-2861- OSBOE-2864	Order of Probation with Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	



Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1143	OSBOE-2865- OSBOE-2868	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1144	OSBOE-797- OSBOE-800	Finding of Fact, Conclusion of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1145	OBD-9296- OBD-9299	Agreed Order of Suspension (Stayed) and Probation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1146	OKMB-5421- OKMB-5434	Order of Suspension of Medical License	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1147	OKMB-17321- OKMB-17328-	Order Accepting Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1148	OSBOE-1732- OSBOE-1740	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1149	OSBOE-1950- OSBOE-1953	Finding of Fact, Conclusion of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1150	OKMB-7120- OKMB-7122[H]	Final Order of Reprimand, Administrative Fine and Community Service	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1151	OKMB-7140- OKMB-7144	Voluntary Submittal to Jurisdiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1152	OKMB-7123- OKMB-7126	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1153	OKMB-7203- OKMB-7205	Order Accepting Voluntary Surrender of License In Lieu of Prosecution	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
1154	OKMB-7184- OKMB-7189	Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1155	OSBOE-817- OSBOE-821	Finding of Fact, Conclusion of Law and Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1156	OSBOE-2605- OSBOE-2611	Finding of Fact, Conclusion of Law and Agreed Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1157	OSBOE-2017- OSBOE-2022	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1158	OSBOE-2006- OSBOE-2011	Order of Probation with Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1159	OSBOE-1724- OSBOE-1727	Emergency Order of Suspension Pending A Hearing	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1160	OSBOE-1718- OSBOE-1723	Modified Order of Probation with Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1161	OBN-60118- OBN-60135	Final Order	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1162	OSBOE-4662- OSBOE-4665	Order of Suspension with Conditions	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1163	OSBOE-4684- OSBOE-4693	Amended Complaint	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
1164	OBN-61300- OBN-61324	Final Order Including Findings of Fact and Conclusion of Law	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	